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(57) ABSTRACT 
The present invention relates to compounds which bind to the 
hydrophobic pocket of the B clamp, i.e., to the surface of the 
Bring with which said protein interacts with other proteins of 
the bacterial replication complex during DNA replication. 
These compounds are derived from the acetylated peptide 
AcOLDLF (P6) to improve their affinity to their target. 
16 Claims, 11 Drawing Sheets 
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1. 
COMPOUNDS BINDING TO THE BACTERIAL 
BETARING 
SEQUENCE LISTING SUBMISSION VIA 
EFS-WEB 
A computer readable text file, entitled “045636-5242-Sub 
stituteSequenceListing..txt created on or about 14 Apr. 2015, 
with a file size of about 13 kb contains the sequence listing for 
this application and is hereby incorporated by reference in its 
entirety. 
The present invention relates to bacterial replication. More 
precisely, the present invention concerns compounds which 
bind to the hydrophobic pocket of the B clamp, i.e., to the 
5 
10 
2 
interacting pockets potential targets for the development of 
new antibacterial oranticancer drugs, respectively. In a recent 
report, a chemical compound was identified from a library 
and shown to bind into the leucine rich sub-domain of the E. 
coli Bring interacting pocket with an affinity of 10 M'. 
In the experimental work described below, a different, 
structure-based strategy was used to design short peptides 
with improved affinities for the B interacting pocket. The first 
step of this approach was to decipher the molecular basis of 
the interaction of the natural ligand in the binding pocket. 
Then, using these data, a first peptide (SEQID No. 6, P6) was 
designed, which was then further modified to improve its 
affinity. Several biophysical and biochemical methods were 
used to measure the strength of the interaction and to charac 
terize the structure of the most efficient complexes formed. As 
surface of the Bring with which said protein interacts with 15 a. result, the binding efficiency of the modified ligand was 
other proteins involved in DNA metabolism. 
In all three domains of life, multicomponents complexes, 
the so-called replisomes, have evolved to ensure the faithful 
replication of chromosomal DNA. One central protein of 
these complexes forms a ring that encircles and slides along 
the double stranded DNA' . A physical interaction between 
the clamp and the chromosomal replicase confers a high 
improved by two orders of magnitude, reaching 10 M 
range. 
Due to their very good affinity for the B interacting pocket, 
the compounds described in the present text are very prom 
ising leads for new antibiotic compounds. 
According to a first aspect, the present invention pertains to 
a compound of formula (I) 
(I) 
O RI R2 O R4 
R NH-1a Gln NH NH O1, NH NH NH Y R6 
O O O R3 O R5 
processivity to the enzyme. In bacteria, the processivity fac 
tor, also referred to as the Bring, is a homodimer which results 
from the head-to-tail association of two monomers, each of 
them being shaped in three globular sub-domains. In eukary 
otes and archae, the B homolog factor, PCNA (for Proliferat 
ing Cell Nuclear Antigen), is a homotrimer with each mono 
mer organized in two sub-domains’. 
Beside their role as processivity factors for chromosomal 
replicases, B and PCNA clamps also participate in various 
protein-protein interactions. They notably act as landing plat 
forms for factors involved in DNA metabolism and cell cycle 
regulation, particularly DNA polymerases involved in trans 
lesion synthesis'', and factors promoting DNA repair' '. 
All these factors possess a small conserved peptide sequence, 
which binds into a hydrophobic pocket located on one side of 
the ring. Noteworthy, these pockets differ significantly 
between bacterial rings and PCNA. A bioinformatics analysis 
performed on putative Bring partners led to define the bacte 
rial consensus binding peptide QLIS/DLF'. The absolute 
requirement of the interacting peptide for B ring partners 
binding has been further demonstrated biochemically and 
physiologically'' ' ' '. Finally, the interaction between 
the ring and the interacting peptide of different B binding 
proteins have been structurally characterized' ' ' ' The 
peptide binding site is formed by a deep leucine-rich hydro 
phobic pocket (subsite 1) located between sub-domains two 
and three of the 3 monomer and connected via a groove to a 
second sub-site (subsite 2) located in sub-domain three' 
(FIG.1C). An additional interaction has also been observed in 
the case of the polymerase Pol IV, between the little finger 
domain of the enzyme and the edge of the Bring'. 
The major contribution of the peptide-mediated interaction 
to a successful DNA replication and ultimately to cell Sur 
vival, both in prokaryotes and eukaryotes, makes the ring 
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wherein 
Gln is glutamine; 
R is selected in the group consisting of a C-alkyl group 
optionally Substituted by a Co-o-aryl group, a C2-12 
alkenyl group optionally Substituted by a Co-aryl 
group, a C-cycloalkyl group, a Co-aryl group 
optionally Substituted by a C-alkyl, and a C-s-alkyl 
(O—CH2—CH) group with t being an integer from 
0 to 20 inclusive; 
R" is the side chain of arginine or lysine (n.b.: when n>1, 
each R' is, independently from each other, the side chain 
of arginine or lysine); 
R is a -(CH2)—Co-cycloalkyl group optionally substi 
tuted by a halogen and/or by a group selected amongst 
NH, -NH CO-R, COH, -NHR and 
NR'R'', wherein R and Rare independently a C 
alkyl group; 
R is selected in the group consisting of a C-s-alkyl group, 
the side chain of arginine or lysine. —(CH2) CO.R.", 
—(CH2) CO. NHR'. , —CHOR and — (CH), 
NHR, wherein 
q is 1, 2, 3 or 4. 
R" is a hydrogen atom, a C-8-alkyl group, a C4-12 
alkylene group forming together with Ralactone or 
a polyether ring, or a C2-alkenylene, forming 
together with Ralactone or a polyether ring, 
R’ is a hydrogenatom, a C-s-alkyl group, or—(CH2)g 
—NH with q' being an integer between 2 and 8 
inclusive and forming together with Ralactam, 
R is a hydrogen atom, a C-s-alkyl group, a C4-12 
alkylene group forming together with Ralactone or 
a polyether ring, or a C2-alkenylene, forming 
together with Ralactone or a polyether ring, 
US 9,133,240 B2 
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R is a hydrogen atom, or R together with R' form a 
lactam, 
R" is a C-s-alkyl group optionally substituted by a Co 
cycloalkyl group, or a halogen-Ca-alkyl group: 
R is selected in the group consisting of a -(CH2)—Co 
cycloalkyl group; —(CH2—CH)—C-cycloalkyl 
group; a —(CH)—Co-aryl group optionally substi 
tuted by a halogen, a C- alkyl group and/or a C 
alkoxy group; a —(CH-CH)—Co-aryl group 
optionally substituted by a halogen, a C- alkyl group 
and/or a C- alkoxy group; a —(CH2)—Cs-o-het 
eroaryl group optionally Substituted by a halogen and/or 
a C- alkyl group; a —(CH2—CH2)—Cs-o-heteroaryl 
group optionally substituted by a halogen and/or a C 
alkyl group; 
Ris-COH,-COR, CO. NH CO. NHR'. 
—OR' when ris 1 or 2, -NH CO. NHR' when ris 
1 or 2, or R is CO , —CO O— or - O - and 
forms a lactam, a lactone, or a polyether ring with R', 
R7, R or R; wherein 
R" is a C-s-alkyl group optionally substituted by a 
Co-o-aryl group; a C-cycloalkyl group; a Co-o- 
aryl group optionally substituted by a halogen, a C 
alkyl group and/or a C2-alkoxy group; 
m is 0 or 1; 
n is an integer from 0 to 9 inclusive; 
p is an integer from 0 to 10 inclusive; 
r is 0, 1 or 2. 
In the above formula (I), the peptide linkages (—CO— 
NH ) can be replaced or modified to obtain synthetic 
pseudopeptides or peptidomimetics in which the peptide 
bond is modified, especially to become more resistant to 
proteolysis, provided the immunogenicity of and the toxicity 
of the molecule is not increased by this modification, and 
providing the pseudopeptide retains its affinity for the B inter 
acting pocket. 
The following definitions are set forth to illustrate and 
define the meaning and scope of the various terms used to 
describe the invention herein. The term “C-2-alkyl refers to 
a branched or straight-chain monovalent saturated aliphatic 
hydrocarbon group of 1 to 12 (inclusive) carbonatoms. Simi 
larly, the terms: “Cs-alkyl”, “Cis-alkyl”, “C-alkyl”. 
“C-alkyl and the like refer to branched or straight-chain 
monovalent Saturated aliphatic hydrocarbon groups of 
respectively, 1 to 8 (inclusive), 1 to 5 (inclusive), 1 to 4 
(inclusive), 1 to 2 carbon atoms. This term is further exem 
plified by groups as methyl, ethyl, propyl, butyl, pentyl, 
hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecanyl and 
their branched isomers. The “alkyl group can optionally be 
mono-, di-, tri- or multiply-substituted by a halogen and/or a 
Co aryl group, as defined below. 
The term “Cs-alkyl-(O—CH2—CH)-” refers to a 
—(O—CH2—CH) - Substituted Cis-alkyl group wherein 
the alkyl group is as defined above and t is an integer from 0 
to 20 (inclusive), preferably 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. 
Preferred—(O CH-CH), substituted alkyl group is a 
Cs-alkyl-(O—CH2—CH2) - group with t and alkyl as 
defined above. 
The term "C-2-alkenyl refers to a branched or straight 
chain monovalent unsaturated aliphatic hydrocarbon group 
having one or more carbon double bonds, of 2 to 12 (inclu 
sive) carbon atoms, preferably 2 to 8 (inclusive) carbon 
atoms, more preferably 2 to 4 (inclusive) carbon atoms. This 
term is further exemplified by groups as vinyl, propylenyl, 
butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, dece 
nyl, undecenyl, dodecenyl and their straight-chain and 
branched and stereo isomers. The “alkenyl group can 
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optionally be mono-, di-, tri- or multiply-substituted by a 
halogen and/or a Co-aryl group, as defined below. 
The term "C2-alkylene' refers to a divalent C2-alkyle 
with alkyl as defined above. Similarly, terms such as "C2 
alkylene' or “Cas-alkylene' and the like, refer to divalent 
C2-alkyl or divalent Cas-alkyle group where alkyl is 
defined above. Examples of alkylene groups are —(CH)—, 
(CH) , —(CH) , —(CH) , —(CH2) , 
(CH) , —(CH), , —(CH) , —(CH) , 
(CH2)o s (CH2) s (CH2)2 
The term "C2-alkenylene' refers to a divalent C.- 
alkenyl of formula -(CH2), (CH=CH), (CH)- 
whereinx and Zare, independently, 0, 1,2,3,4, 5, 6, 7 or 8 and 
y is 1, 2, 3 or 4. Similarly, the term "Cs-alkenylene', refers 
to a divalent Cas-alkenyl. Examples of alkenylene groups 
includebutenyl, pentenyl, pentadienyl, hexenyl, hexadienyl, 
heptenyl, heptadienyl, octenyl, octadienyl, nonenyl, nonadie 
nyl, decenyl, decadienyl, undecenyl, undecadienyl, undode 
cenyl, undodecadienyl, and their straight-chain and branched 
and stereo-isomers. 
The term "C-cycloalkyl” refers to a saturated or partially 
unsaturated cyclic hydrocarbon group having 3 to 6 (inclu 
sive) carbon atoms. This term is further exemplified by 
groups as cyclopropyl, cyclobutyl, cyclopentyl, and cyclo 
hexyl. The "Ce-cycloalkyl group can optionally be mono-, 
di-, tri- or multiply-substituted by a halogen as defined below, 
a C-alkyl group as defined above, a -NH2, a —NH 
COH, a –NH CO-R, COH, -NHR and/or 
NR'R' wherein R and Rare independently a C-alkyl 
group as defined above. 
The term —(CH)—C-cycloalkyl group refers to a 
—CH2— substituted C-cycloalkyl group wherein the 
cycloalkyl group is as defined above. 
The term “Co aryl” refers to a monocyclic or bicyclic 
aromatic ring system of 6 to 10 (inclusive) carbon atoms, 
preferably 6 carbonatoms. This term is further exemplified by 
groups as phenyl and naphtyl. The Co-aryl group can 
optionally be mono-, di-, tri- or multiply-substituted by a 
halogenas defined below and/or a C-alkyl group as defined 
above. 
The terms “halo' or “halogen' refers to fluorine, chlorine, 
bromine and iodine. 
The term "halogen-Ca-alkyl, refers to a halogen Substi 
tuted C-alkyl group wherein both halogen and alkyl groups 
have the meaning as above. Preferred “halogen-C -alkyl 
groups are fluorinated "halogen-Ca-alkyl groups such as 
—CF, —CH CF, —CH(CF), —CH(CH)(CF), 
—CF. 
The term “C-alkoxy” refers to a branched or straight 
chain monovalent saturated aliphatic hydrocarbon group of 1 
to 12 (inclusive) carbon atoms attached to an oxygen atom. 
Similarly, the terms "Cs-alkoxy”, “Cis-alkoxy”, “C- 
alkoxy”, “C-alkoxy' refer to branched or straight-chain 
monovalent Saturated aliphatic hydrocarbon groups of 
respectively, 1 to 8 (inclusive), 1 to 5 (inclusive), 1 to 4 
(inclusive), 1 to 2 carbon atoms. Examples of “alkoxy” 
groups are methoxy, ethoxy, propoxy, butoxy, pentoxy, hexy 
loxy, heptyloxy, octyloxy, and their branched isomers. 
The term “Cso-heteroaryl refers to a heterocyclic aryl 
group containing 1 to 3 heteroatoms in the ring with the 
remainder being carbon atoms. In the said heterocyclic aryl 
group, Suitable heteroatoms include, without limitation, Sul 
fur and nitrogen. Exemplary heteroaryl groups include 
indolyl azaindolyl, thiophenyl, benzothiophenyl, thioazolyl, 
benzothiazolyl. The heteroaryl group can optionally be 
mono-, di-, tri- or multiply-substituted by a halogen and/or a 
C-alkyl group, as defined above. When the heteroaryl 
US 9,133,240 B2 
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group is mono-, di-, tri- or multiply-substituted by a C 
alkyl group, said alkyl group is preferably a methyl group. 
The term “polyether ring, refers ring containing 1, 2, or 3 
ether groups, an ether group being an oxygenatom connected 
to two alkyl groups as defined above 
The term "lactone” refers to a closed ring containing an 
oxygen atom adjacent to a carbonyl group (-CO-O ). It 
can be considered as the condensation product of an —OH 
group with a —COH group. 
The term “lactam' refers to a closed ring containing an 
nitrogenatom adjacent to a carbonyl group (-CO—NH- or 
—CO NR— with R being for example an alkyl group as 
defined above). 
The terms "substituted” and “substitution and the like”, 
refer to the replacement of one, two, three or more atoms in a 
given group by one, two, three or more Suitable Substituents, 
including, without limitation, a halogen, a Co aryl group, a 
C-alkyl group, a C-2-alkyl group, a C-2-alkoxy group, a 
- NH, a NH CO R', -COH, -NHR'' and/or 
—NR'R' wherein R* and Rare independently a C-alkyl 
group, or a mixture of those Substituents. 
In some embodiments of the invention, the compounds of 
the invention can contain one or more asymmetric centers and 
thus occur as racemates and racemic mixtures, single enanti 
omers, individual diastereoisomeric mixtures. All Such iso 
meric forms of these compounds are included in the present 
invention, unless expressly provided otherwise. 
In some embodiments, the compounds of the invention can 
contain one or more double bonds and thus occur as indi 
vidual or mixtures of Z and/or E isomers. All such isomeric 
forms of these compounds are included in the present inven 
tion, unless expressly provided otherwise. 
In the embodiments where the compounds of the invention 
can contain multiple tautomeric forms, the present invention 
also includes all tautomeric forms of said compounds unless 
expressly provided otherwise. 
In the embodiment where R' together with R' form a 
lactone or a polyether ring, 
R" is Ca2-alkylene, preferably Cas-alkylene group, and 
is linked to a —CO—O— or to a —O— functional 
group in R, or 
R" is Ca2-alkenylene, preferably Cas-alkenylene group, 
and is linked to a —CO-O- or to a —O—functional 
group in R. 
In the embodiment where R' together with R' form a 
lactam, Risa (CH), CO. NHR'' and R” is -(CH.), 
—NH with q' being 2, 3, 4, 5, 6, 7 or 8. 
In the embodiment where R together with R' form a lac 
tam, R is a -(CH.)NHR' and R is a direct link between 
-(CH2)NH- and a —CO functional group in R. 
In the embodiment where R together with R' form a lac 
tone or a polyether ring: 
R is C2-alkylene, preferably Cas-alkylenegroup, and is 
linked to a —CO—O— or to a —O—functional group 
in R, or 
R is Ca2-alkenylene, preferably Cas-alkenylene group, 
and is linked to a —CO-O- or to a —O—functional 
group in R. 
The terms “Bring”, “B protein’ or “B clamp’ herein des 
ignate the B subunit of a eubacterial DNA polymerase III, 
such as that of E. coli. The B subunit of DNA polymerase III 
of E. coli is in particular described in Kong et al. (1992)". 
Further definitions are added in the text, when necessary. 
Particular embodiments of the compounds according to the 
invention are described in the following more detailed speci 
fication. 
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6 
According to a particular embodiment of the compounds 
according to the invention, the R group indicated in the above 
formula (I) is selected amongsta Cis-alkyl group optionally 
Substituted by a Co-o-aryl group, a C2-s-alkenyl group 
optionally substituted by a Co-aryl group or a C-s-alkyl 
(O—CH2—CH) group with theing 0, 1, 2, 3, 4, 5, 6, 7, 8, 
9 or 10. Preferably, R is a C-alkyl group optionally substi 
tuted by a Co-aryl group or a C-alkenyl group optionally 
Substituted by a Co-aryl group. Indeed, as described in the 
experimental part below, the inventors have observed that a 
N-terminal acetylation of the peptide P5 (QLDLF, SEQ ID 
No. 5) leads to a 10-fold increase of the affinity of the peptide 
for the 3 interacting pocket. 
When m is not null and p is >1 in the above formula (I), for 
example when m=1 and p=2, 3, 4, 5, 6, 7, 8, 9 or 10, the 
above-described compounds are pegylated. The pegylation 
contributes to the stability of the whole molecule and can also 
have a positive effect for the entry of said compound into 
bacterial cells. 
Particular compounds according to the invention have one 
or several arginines and/or lysines at the N-terminal extremity 
of the peptide part of the compound. For example, n is 1, 2, 3, 
4 or 5. Indeed, these positively charged residues are known to 
favor membrane crossing. This feature is however not com 
pulsory, and other compounds according to the invention do 
not have such residues (n=0 in formula I). 
The inventors have also observed that substitution of the 
second amino acid of Ac-QLDLF (SEQ ID No. 6, P6) by a 
beta-cyclohexyl-L-alanyl (hereafter designated as “Cha’) 
leads to a further 6-fold increase of the affinity of said peptide 
with the B hydrophobic pocket. Other substitutions at the 
same position (see Table 4 in the experimental part) led to the 
above definition of R in formula (I). According to an advan 
tageous embodiment, R is a -(CH2)—Cle-cycloalkyl 
group. 
By substituting the leucine of the acetylated peptide Ac 
Gln-Cha-Asp-Leu-Phe7 (SEQID No. 7, P7) by a number of 
different residues (see Table 5 of the experimental part 
below), the inventors could determine preferable embodi 
ments for R group, in order to optimize the binding to the 
interacting pocket of the fring. Accordingly, R is preferably 
selected amongst Cis-alkyl groups, especially branched ones 
(such as Valine, leucine or homoleucine lateral chains, for 
example), or amongst C. , preferably C2-alkyl groups 
optionally Substituted by a C-cycloalkyl group (such as 
Cha and homoCha, for example). 
As shown in Table 6 below, modifications introduced on 
the C-terminal phenylalanine benzyl ring led to an increase of 
the affinity of the molecule with the interacting pocket of the 
Bring. The binding affinity was found to increase with the size 
of the ring substituent (p-methyl-p-chloro-p-bromo-3,4- 
dichloro). The same table shows that other cyclic molecules 
can be used in this position. Contrarily, replacement of the 
phenylalanine lateral chain by a 2-amino-tetradecanoic acid 
led to a significant loss in affinity, thereby indicating an upper 
limit for the size of the group to be used at this position. 
Accordingly, in the compounds of the present invention, R is 
preferably a -(CH2)—Co-aryl group optionally Substi 
tuted by a halogen, a C- alkyl group and/or a C- alkoxy 
group. 
As exemplified in the experimental part below, excellent 
affinities are obtained with linear molecules having a peptidic 
skeleton. Such molecules excellently mimic the binding part 
of the proteins which naturally interact with the fring. When 
the compounds according to the invention are linear, Rand 
Rare as follows: 
US 9,133,240 B2 
7 
R is selected in the group consisting of a C-s-alkyl group, 
the side chain of arginine or lysine. —(CH) CO.R7, 
—(CH2) CO. NHR'. , —CHOR, (CH), 
NHR, wherein 
q is 1, 2, 3, 4, 5 
R" is a hydrogen atom, or a C-s-alkyl group, 
R’ is a hydrogen atom, or a Cis-alkyl group, 
R is a hydrogen atom, a C-s-alkyl group, 
R is a hydrogen atom; 
and 
R is COH, COR', CO. NH CO. NHR'. 
—OR' when ris 1 or 2, NH CO. NHR' when ris 
1 or 2; wherein 
R" is a C-s-alkyl group optionally substituted by a 
Co-o-aryl group; a C-cycloalkyl group; a Co-o- 15 
aryl group optionally substituted by a halogen, a C 
alkyl group and/or a C2-alkoxy group. 
It is to be noted that R is directed towards the solvent. 
Hence, R can be replaced by virtually any kind of molecule. 
For example, it can advantageously be replaced by or attached 
to a molecule which helps the crossing of membranes and/or 
the internalization by the bacteria. Non-limitative examples 
of such molecules are cell-penetrating peptides (CPP) 
(Classes and prediction of cell-penetrating peptides, 
Lindgren M. Langel U. Methods Mol Biol. 2011, 683, p. 
3-19). In case a CPP or another molecule is covalently bound 
to the compound via R', a linker, made of one to 10, prefer 
ably 1 to 4 amino acids, can be added between the compound 
of the invention and said CPP. Such a linker can be, for 
example, a mere arginine or lysine, or a sequence of 2 to 4 
amino-acids corresponding to the amino-acids immediately 
following the binding site of a natural ligand of the Bring, 
such as, for example, ASRO (SEQID No. 31), which is the 
sequence following the binding site of the delta protein from 
the gamma complex. Indeed, as shown by Jeruzalmi et al 
(2001)''', this protein exhibits a bend towards the outside 
of the pocket. Hence, a CPP bound via a ASRO linker to a 
compound according to the invention would not hinder the 
interaction of said compound with the Bring. 
According to a particular embodiment of the linear com 
pounds of the present invention, Rand/or Rare as follows: 
R is selected in the group consisting of the side chain of 
arginine, the side chain of lysine. —(CH2) CO.R" 
and —(CH2) CO. NHR'. wherein 
q is 1, 2, 3 or 4. 
R" is a hydrogen atom, or a C-s-alkyl group, and 
R’ is a hydrogen atom, or a Cis-alkyl group, 
and/or 
R is -COH or -CO. NH. 
In an alternative embodiment, the compounds according to 50 
the present invention are cyclic, a cycle being made between 
the RandR groups. This bridge between R and R groups 
eliminates carboxylates, thereby improving the capacity of 
the compounds to enterbacterial cells, without impacting R5, 
which is necessary for anchoring the compound in the pocket, 55 
and for the Subsequent conformational modification of said 
pocket. According to this embodiment, Rand Rare as fol 
lows: 
R is selected in the group consisting of -(CH2)g 
COR7, -(CH.) CO. NHR'. , CHOR, 
—(CH.)NHR, wherein 
q is 1, 2, 3 or 4. 
R" is a Cas-alkylene group forming together with Ra 
lactone or a polyether ring, or a Cas-alkenylene, 
forming together with Ralactone or a polyether ring, 
R7 is (CH) NH- with q' being an integer from 2 
to 8 inclusive and forming together with Ralactam, 
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R is a Cas-alkylene group forming together with Ra 
lactone or a polyether ring, or a Cas-alkenylene, 
forming together with Ralactone or apolyether ring, 
R together with R form a lactam; 
R is —CO , —CO-O or —O—and forms a lactam, 
a lactone, or a polyether ring with R', R', R or R. 
Particular compounds according to the present invention 
are described in the experimental part which follows. Particu 
lar compounds having a very good to excellent affinity for the 
Bring are: P7 (SEQID No. 7), P11 (SEQ ID No. 11), P12 
(SEQ ID No. 12), P13 (SEQ ID No: 13), P14 (SEQ ID No: 
14), P16 (SEQID No: 16), P17 (SEQID No. 17), P23 (SEQ 
ID No. 23), P24 (SEQID No. 24), P25 (SEQID No. 25), P26 
(SEQID No. 26), P27 (SEQID No. 27). 
As described in the experimental part below and as per 
fectly known by skilled artisans, several techniques exist to 
measure the affinity of two interacting proteins. These tech 
niques may give slightly different results. However, the rela 
tive affinity of two compounds for the Bring is not dependent 
from the technique used for measuring said affinities (FIG. 
4B). In a preferred embodiment of the compounds according 
to the invention, the affinity of said compounds for the inter 
acting pocket of the bacterial B ring is at least twice the 
affinity of the acetylated peptide of sequence AcOLDLF 
(SEQID No. 6, P6) with said interacting pocket. 
The compounds described above can advantageously be 
used as antibacterial agents, since they inhibit, at least par 
tially, the interaction between the B protein and proteins that 
interact therewith by binding to its hydrophobic pocket. 
A pharmaceutical composition comprising, as an active 
agent, a compound as above-described, is also part of the 
present invention. 
FIGURES LEGENDS 
FIG. 1: Representations of the ligand binding pocket of the 
Bring of E. coli, from the co-crystal structure of the Bring 
with the C-terminal peptide of the E. coli DNA polymerase IV 
(RQL.V.L.G.L., SEQID No. 32) (PDB code 10K7). A: 
unbound pocket: the Me (A) residue is located close to the 
Has B residue () and obstructs the path between subsite 1 
(black dots area) and subsite 2 (white dots area). Water mol 
ecules are represented as medium grey balls. B. bound 
pocket. The peptide has been removed. The movement of 
residue M opens a cleft (dark arrow) which connects sub 
site 1 and subsite 2 and where the V peptide residue interacts 
(see C). Water molecules are displaced, as compared to A, so 
that the peptide can fit into subsite 1. Note the opening of the 
platform (white star) between M and Res where the L 
peptide residue will be located. C: Same as B but with the 
peptide P1 bound into the pocket. 
FIG. 2: A: Energetic contributions (Kcal/mol) of each pep 
tide residue (RQLVLGL7, SEQ ID No. 32) for the 
interaction within the binding pocket of the B ring (PDB 
1OK7). Black: electrostatic contribution, dark grey: solvent 
accessible surface contribution, light grey: Van der Waals 
contribution, white: total contribution. B: Single residue con 
tribution (kcal/mol) to the peptide binding. Native peptide P1 
of E. coli DNA polymerase IV, from the structure 1 OK7, is in 
black. The pentapeptide P6 is in grey (PDB 3O4J). 
US 9,133,240 B2 
FIG. 3: Detailed connectivities between B residues No 
and M in subsite 2 of the binding pocket, in absence (A) or 
presence (B) of the peptide. Balls represent water molecules. 
From PDB structure 1 OK7, incorporated herein by reference. 
FIG. 4: Polymerase competition assay. A: the B dependant 
activity of PolIV DNA polymerase is challenged by increas 
ing concentrations of various peptides B: the table displays 
the ICso determined for various peptides by the Pol IV based 
biochemical assay and the SPR assay. The histogram indi 
cates that the same general trend is observed with both tech 
niques despite a difference in sensitivity. Grey: biochemical 
assay, black: SPR assay. P15 sequence is Ac-RQLVLF (SEQ 
ID No. 15), Scr: scrambled peptide: Ac-ChaFQLD, (SEQID 
No:33). 
FIG. 5: Superimposition of peptide-B complexes. A: A 
P6-3 complex (pale colors) is superimposed on P12-3 com 
plex (dark colors) (rmsd: 0.95 A). The first (Gln) and last 
(Phe) peptide residues are indicated. The Cha group of P12 
(SEQ ID No. 12) peptide occupies the same position as the 
Leu, residue of P6 (SEQID No. 6). The chloro-modified Phe 
residue of P12 is tilted toward the bottom of subsite 1 as 
compared to the cognate residue of P6. B: P14-3 complex 
(pale colors) is Superimposed on P12-3 complex (dark colors) 
(rmsd: 0.56A). The chlorine atom in metaposition forms an 
halogen bond with T172 residue. 
FIG. 6: Superposition of the peptide free (dark) and peptide 
bound (pale) interacting pockets of 1 OK7 structure. In the 
absence of peptide, the Me side chain (dark) is located close 
to the His residue (closed conformation), and separates Sub 
site 1 and subsite2. When the peptide is bound, the Me side 
chain (pale) is displaced away from the H7s (open confor 
mation) allowing the opening of a cleft in which the peptide 
can bind. Residue Res is also shifted upon peptide binding, 
triggering the opening of a small platform where the peptide 
L. residue locates. 
FIG. 7: Graphical representation of the quantitative analy 
sis of polymerase competition assays performed with several 
peptides. The percentage of inhibition of B dependent E. coli 
DNA polymerase IV activity is plotted as a function of pep 
tide concentration (LM). P15 sequence is Ac-RQLVLF (SEQ 
ID No. 15). Scr: scramble peptide: Ac-ChaFQLD (SEQ ID 
No: 33); (related to FIG. 4). 
FIG. 8: Isothermal titration calorimetry (ITC). 
A. Binding isotherms for the titration of the fring with 
peptide P12 (SEQID No: 12) and P14 (SEQ ID No. 14). N: 
number of sites per B monomer. 
B. Enthalpy–entropy compensation for selected natural and 
non-natural B binding peptides. The thermodynamics param 
eters are determined by ITC. Each value is the mean of two 
independent experiments monitoring the binding of each pep 
tide (400 uM) to the Bring (20 or 30 uM) at 25° C. Each 
correlation point is labeled according to the corresponding 
peptide, and the respective AG values are plotted below. 1 
cal=4.18.J. (related to Table 11). 
FIG.9: Examples of compounds according to the invention 
are represented in FIG. 9 (A-H). Those include compounds 
wherein R-acetyl, cynamoyle, octanoyle; R'-Cl and R-H, 
or R =R=C1, or R' =R=H, or R =Me and R=H, or R'-Br 
and R=H; and R-OH or NH. Specific compounds P23 
(SEQ ID No. 23), P24 (SEQ ID No. 24), P25 (SEQ ID No: 
25), P26 (SEQ ID No. 26), P27 (SEQID No. 27), P28 (SEQ 
ID No. 28), P29 (SEQID No: 29) and P30 (SEQID No:30) 
are disclosed in FIG. 9H. 
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EXAMPLES 
Example 1 
Structure-Based Design of Short Peptide Ligands 
Binding onto the E. coli Processivity Ring 
1.1. Material and Methods 
1.1.1. Protein Production, Purification and Characteriza 
tion 
The E. coli dnaN gene was cloned into pET15b plasmid 
(Invitrogen) using standard protocols. The resulting N-tagged 
protein was expressed in BL21 E. coli cells after IPTG induc 
tion (0.1 mM) at 28°C. The B protein fraction was first 
enriched on a Ni-NTA column, eluted with an histidine step 
(300 mM) and further purified on a MonoO column in buffer 
containing 20 mM Tris HCl pH 7.5, 0.5 mM EDTA and 10% 
glycerol, using a gradient from 0 to 0.5 MNaCl. The quality 
of the protein was assessed by mass spectrometry in denatur 
ing and native conditions 
1.1.2. Peptide Synthesis 
Peptides P1-P14 (SEQID Nos: 1 to 14) were synthesized in 
Fmoc chemistry by the stepwise solid-phase methodology 
on a home-made semi-automatic peptide synthesizer. 
N-N-Fmoc protected amino acids (natural and non natural) 
are commercially available from Polypeptide Labs (Stras 
bourg, France). Resins for Solid-phase peptide synthesis are 
commercially available from Polypeptide Labs (Strasbourg, 
France) and CBL Patras (Patras, Greece). Assembly of the 
protected peptide chains was carried out on a 100-umol scale 
starting from either Fmoc-Leu-Wang resin (Peptides P1, P2, 
P4), Fmoc-Phe-Wang (Peptides P3, P5-P10) resin oro-chlo 
rotrityl chloride resin (peptide P11-P14). For each coupling 
step, the reactants were introduced manually as a solution in 
dry DMF (2.0 mL). No-Fmoc amino acids (5.0 equivalent) 
with standard side-chain protecting groups were coupled 2 
times by using BOP (5.0 equivalent), HOBt (5.0 equivalent) 
and DIEA (10.0 equiv) in dry DMF for 20 min. The washing 
of the resin as well as Fmoc deprotection (by using a freshly 
prepared solution of 20% piperidine in DMF) were per 
formed automatically. The coupling and deprotection steps 
were monitored by the Kaiser test'. At the end of the elon 
gation of the peptidic chain, the resin was washed with 
CHC1 and dried with EtO. A mixture of TFA/HO/TIPS/ 
DTT (8.8/0.5/0.2/0.5; 10.0 mL) was then added to the resin. 
The mixture was gently shaken for 2.5 h and the resulting 
solution was flushed through a frit in cold EtO. The precipi 
tate was recovered by centrifugation, dissolved in a mixture 
of AcOH and H2O and freeze-dried. The crude peptides were 
finally purified by HPLC (linear gradient, 5-65% B, 30 min) 
and freeze-dried. All peptides were identified by matrix-as 
sisted laser desorption/ionization mass spectrometry 
(MALDI-MS), and their homogeneity was assessed by Cs 
RP-HPLC (purity of all peptides determined to be >90%). 
Analytical data are reported in Table 8. 
1.1.3. Molecular Dynamics 
In the present work, the inventors used a protocol based 
on the MM/PBSA method , where conformations 
extracted from molecular dynamics simulations are pro 
cessed using a simplified description for the solvent to yield 
an estimate of binding free energy. Individual contributions of 
each amino acid to the complex formation are estimated and 
important energetic amino acid “hot spots” are identified. 
Structures 
The initial structure for the apo protein was chain A from 
the PDB file 1 OK77, while for the protein and native peptide 
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it was chains B and C from the same PDB (1OK7). All 
crystallographic water molecules were retained. 
MD Simulations 
The CHARMM program, version 32, with the 
CHARMM22 all atom protein-nucleic acid force field was 
used for the molecular dynamics simulations. Hydrogen 
atoms were added using the HBUILD facility in the 
CHARMM program. A sphere of 37 A containing 6840 water 
molecules (TIP3) was used to solvate the system. Stochastic 
boundary conditions were imposed and the calculation was 
limited to residues 7 A around the peptide. The SHAKE 
algorithm was used to constrain hydrogen-heavy atom bond 
distances, and the simulations were done using Langevin 
algorithm. A 1-fs time step was used for the molecular 
dynamics simulation and the simulation time. A 12 A cutoff 
was used; the van der Waals non bonded terms were treated 
with a SWITCH potential function whereas the electrostatic 
terms was evaluated with the SHIFT function. 
Free Energy Decomposition of Interactions Between the E. 
coli B Clamp and the Different Peptides. 
To obtain a semi-quantitative estimate of the contributions 
of all amino acids to the binding free energy for the formation 
of the 3 clamp-peptide complex, a molecular free energy 
decomposition scheme based on the Molecular Mechanics/ 
Poisson-Boltzmann Surface Area (MM/PBSA) analysis was 
performed, following the approach presented by Lafont et 
al.'. From this analysis, an estimation of the free energy of 
binding for molecular complexes can be obtained. Briefly, in 
the MM/PBSA approach, the free energy is estimated using a 
standard thermodynamic cycle of the form 
AG8'ss 
Prot + Peptide - > Prot:Peptide 
|AGProtein, AGPeptide, |AGcomple, 
AG solution 
Prot + Peptide Prot:Peptide 
where the binding free energy is calculated according to the 
equation: 
solution gas AGassoc AEAff-TAS+Ma?t-AGaiti, 
where A* is the difference in the gas phase energy; 
AS is the change in entropy upon complex formation and 
AG, is the change in Solvation free energy. The gas 
phase energy differences contain terms for the intermolecular 
electrostatic and Vander Waals energies, as well as the equiva 
lent internal energy terms. These terms are based on the 
CHARMM force field in the present approach. The solvation 
free energy is divided into two contributions: an electrostatic 
and a nonpolar contribution. This latter term is approximated 
by an empirical relationship based on Solvent accessible Sur 
face area and the electrostatic contribution is calculated here 
using the Poisson-Boltzmann equation. 
Several approximations are introduced in the MM/PBSA 
method. The first was the neglect of conformational change 
upon complex formation, which is dictated by the absence of 
experimental structures for the unbound protein and peptides. 
To account for the unbound species in the calculations, their 
respective structures were obtained from the complex gener 
ated during the molecular dynamics simulations. With this 
approximation, there are no changes to the internal energy 
terms. The second approximation is the neglect of changes in 
configuration entropy due to binding. Although these simpli 
fications preclude calculations of absolute values of the bind 
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ing free energies, they have been shown in previous work to 
be satisfactory in the context of identifying interaction energy 
"hot spots” in protein-protein and protein-ligand complexes. 
Similar simplifications have been employed in other studies' 
31. 37. Via this approach, the total binding free energy can be 
decomposed into individual energetic contributions per resi 
due. Decomposition of the binding free energy to individual 
amino acid contributions leads to the identification of amino 
acids that play a dominant role in binding and can contribute 
to reliable predictions of the role of particular amino acids in 
stabilizing complexes. 
1.1.4. Structure-Based Design of Peptides 
From the initial structural and energetic analysis of the 
RQLVLGL (SEQID No. 1, P1 in Table 1) peptide binding to 
the B clamp, modification of the sequence appeared poten 
tially interesting in three positions (cf. FIG.1): Q2; L3 and the 
hydrophobic L5-G6-L7 segment. In order to identify inter 
esting modifications, the programs MCSS and SEED 
were used to dock small librairies of hydrophobic and polar 
Small ligands (fragments) onto the Surface of the B-clamp 
encompassing the peptide binding site. The protocol incor 
porated improved scoring functions with Solvation correc 
tions.' '. From this initial step, it appeared difficult to find 
replacements for the Q2 side-chain of the peptide that would 
correctly maintain the intricate hydrogen-bond network at 
this position (see FIG. 3) and therefore no modification of Q2 
were attempted. For the other positions, improving interac 
tions with optimized hydrophobic contacts appeared promis 
ing. Based on these initial data, a selection of peptides with 
modified side chains were constructed, docked into the struc 
ture and their interactions with the B clamp evaluated using 
the MM-PBSA protocol described above. The choice of side 
chain replacements was based on the docking data, focusing 
on commercially available protected amino-acids. A force 
field adapted from CHARMM22 was used for non-natural 
amino acids. The most promising candidates were selected 
for synthesis. 
1.1.5. B/Peptide Interaction in Solution: In Vitro Competi 
tion Assays. 
5' end radiolabelling, purification and annealing of syn 
thetic primers were performed as previously described (Wag 
ner et al., 1999). The 30/90mer synthetic construct was 
obtained by annealing the 30 mer primer (5'GTAAAAC 
GACGGCCAGTGCCAAGCTTAGTC3', SEQ ID No. 34) 
with the 90 mer template (5 CCATGATTACGAATTCAGT 
CATCACCGGCGCCACAGACTAAGCTTGGCACTG 
GCCGTCGTTTTACAACGTCGTGACTGGGAAAA 
CCCTGG3, SEQID No:35) to form a double stranded struc 
ture with 5' and 3' ssDNA overhangs of 25 and 35 nucleotides, 
respectively. All replication experiments (10 ul final volume) 
were carried out in buffer E (40 mM HEPES pH 7.5, 80 mM 
potassium glutamate, 160 ug/ml BSA, 16% glycerol, 0.016% 
NP40, 8 mM DTT). The 30/90 mer duplex (1 nM final con 
centration) was first incubated with single strand binding 
protein (SSB; Sigma; 90 nM final concentration) in the pres 
ence of ATP (200 uM) and MgCl, (7.5 mM) at 37° C. for 10 
min. Y complex (1 nM final concentration) (obtained as 
described by Dallmann et al., 1995) and B clamp (5 nM as 
dimer final concentration) were added at that stage and incu 
bation was carried out at 37° C. for 10 min. Then, 7 ul of the 
mixture was added to 1 ul of either DMSO or 1 ul of peptide 
Solution (as specified), incubated 5 min. at room temperature 
and further 2 hours at 4°C. 1 ul of PolIV was then added (1.5 
nM final concentration), incubated 5 min. at room tempera 
ture and finally, the whole reaction was mixed with 1 ul of a 
dNTPs solution (200 uMeach dNTP final concentration) and 
let react for 1 min. at room temperature. Reactions were 
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quenched by the addition of 20 ul of 95% formamide/dyes 
solution containing 7.5 mM EDTA, heat-denatured and 
analysed by chromatography on 12% denaturing polyacryla 
mide gels. Radiolabelled products were visualised and quan 
tified using a Personal Molecular Imager FX and the Quantity 
One software (Bio-Rad). 
1.1.6. SPR Assays. 
SPR experiments were performed on a Biacore R 3000. 
The association constant (K) of B with the natural Cter 
heptamer (P1, Table 7) of the DNA polymerase IV of E. coli 
were determined as follow: the B protein (0.125 uM to 2 uM) 
was injected on the immobilized P1 peptide at a flow rate of 
500 uL'min'. After subtraction of the background response, 
the data were fit to the 1:1 Langmuir model using BIAevalu 
ation (BiacoreTM). The inhibition of P1-B interaction by pep 
tides P2 to P14 (Table 7) was used to measure their affinity for 
B and was assessed according to the following procedure: 
complexes of Bring (0.25uM) with various concentrations of 
challenging peptides (1.5 nM to 100 uM) were formed and 
injected on a chip loaded with the P1 peptide. ICs values for 
each challenging peptide were determined by plotting the 
concentration of peptide against the percentage of binding 
inhibition. The ICs value of each peptide was used to calcu 
late Ki (Ki =(1+KB)/ICs) which measures the affinity of 
the challenging peptide for B in the competition assay, and AG 
was derived from Ki (AG=RT ln Ki). 
1.1.7. Isothermal Titration Calorimetry. 
ITC was performed by using a ITC200 microcalorimeter 
from MicroCal. Peptides (400 uM) were titrated in sequential 
injections (2 Jul each) into a B ring solution (300 ul, 20 or 
30 uM) at 25°C. Data were corrected from control experi 
ments where peptides were injected in buffer solution (Hepes 
10 mM pH 7.4, NaCl 0.15M, EDTA 3 mM, P200.005%). 
Data analysis was performed with Origin 7.0 software. 
1.1.8. Crystallogenesis, Data Collection and Processing. 
Crystallization experiments were essentially conducted as 
described previously''. Crystals of P12-f complexes were 
grown in capillaries in presence of 0.2% of agarose'. Crys 
tallisation buffer contained 100 mM CaCl, 100 mM Mes pH 
6.0 and 30% PEG 400. Cryoprotection was performed by 
soaking crystals in the same buffer supplemented with 20% 
glycerol. Cryoprotected crystals were frozen in liquid ethane 
and X-ray diffraction data were collected at 100 K at beam 
lineX06SA at the Swiss Light Source (Villigen PSI, Switzer 
land) and beamlines ID29 and ID 14-4 at ESRF (Grenoble, 
France). Diffraction images were processed with XDS, 
XSCALE and XDSCONV. The structures were solved by 
molecular replacement with MOLREP'', using the known 
beta structure as a search model PDB ID 1 OK7°. Alternate 
rounds of rebuilding and refinement, including noncrystallo 
graphic symmetry restraints, were carried out with 
PHENIX, COOT and CNS7. Model statistics were 
obtained with Molprobity". Molecular visualizations and 
structures illustrations were performed using PyMOL. Data 
processing and refinement statistics are Summarized in Table 
11. 
1.2. Results 
1.2.1. Structure and Energetics of the Binding Pocket 
The inventors have previously solved the structure of a 
complex formed between the E. coli B clamp and the 16 
residues long C-terminal peptide of the E. coli DNA poly 
merase IV (PDB code: 1.OK7)'7. A first part of the present 
work aimed at unraveling the molecular basis of the peptide 
pocket interactions. Molecular modeling approaches were 
used to determine the contribution of each residue of the last 
seven amino-acids of the C-terminal part of Pol IV 
(RQLVLGL7, SEQID No. 32) to the overall interaction 
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(FIG.2A), using free energy decomposition (see Material and 
Methods). For each amino acid, the van der Waals, electro 
static and hydrophobic solvation contribution to binding have 
been calculated. Stabilizing interactions between the Bring 
and the peptide are essentially Van der Waals contacts (see 
FIG. 2A). Electrostatics contributions are poor, due to com 
pensation between the protein-peptide interaction and the 
peptide desolvation cost. Hydrophobic solvation contribu 
tions are favorable but of lesser magnitude. The net contribu 
tions of residues Q2, L3, L5 and L, is predominant to the 
overall interaction (FIG. 2B). G has no contribution while V. 
which is oriented toward the solvent poorly contributes to the 
interaction. 
Due to the good resolution, the inventors could also ana 
lyze the position of water molecules in the free and bound 
pockets of the 1OK7 structure. In the absence of peptide, four 
water molecules are located in subsite 1. Upon peptide bind 
ing, one is eliminated and one is repositioned close to the Ta 
and Ysa residues, allowing the Ls-Go-L7 tripeptide to bind 
into the hydrophobic subsite 1 (FIG. 1AB). The two water 
molecules located on the platform in the apo monomer are 
dislodged upon peptide binding, thus making room for the 
peptide L. residue to bind (FIG. 1BC). Finally, two water 
molecules are deeply inserted into the empty subsite 2. One of 
these two molecules interconnects the NH of No and the 
CFO of Me (FIG.3) and is not exchanged with the solvent 
upon peptide binding, underlining its structural function. The 
second water molecule is replaced by the C6-0 of peptide Q2 
residue, while its 8-amino group establishes bounds with the 
CO-O of M and the CO-O of peptide residue L (FIG.3B). 
This initial analysis led the inventors to design a minimal 
peptide binding sequence that was used as a starting point for 
ligand optimization. Because of the complex network of 
hydrogen bonds formed by the highly conserved Q residue in 
Subsite 2, one cannot Substitute this side chain without dra 
matically altering the interaction of the whole peptide. Alter 
natively, several other positions in the peptide sequence may 
accept modifications that could increase its affinity for the B 
clamp. Following the structural and energetic analysis of the 
binding pocket (see Material and Methods), several peptides 
were synthesized (Table 7 and Table 11) and their binding 
efficiencies were analyzed by Surface plasmon resonance 
(SPR). The dissociation constant of the P1 natural heptapep 
tide was measured to be 2.85 (+0.94) 107M. As compared to 
the whole polymerase, this peptide binds 30 fold less effi 
ciently to the ring (table 1, compare P1 and PoliV), pinpoint 
ing the contribution of alternate regions of the enzyme to the 
interaction'' '' ' Removing the G residue of the terminal 
tripeptide (-LGL) results in a two to three fold decrease in 
interaction (table 1, compare P1 and P2), while replacing the 
terminal tripeptide with the consensus LF dipeptide does not 
affect the affinity (table 1, compare P1 and P3). However, a 
FL dipeptide totally disrupts peptide binding (table 1, P4). 
Substituting F for other aromatic residues (W.Y) at the C-ter 
minal position does not contribute to any increased interac 
tion (data not shown). In order to design the shortest peptide, 
the first (R) residue was also removed, which does not seem 
to contribute significantly to the binding (table 1, P5, FIGS. 1 
and 2)", and the V was replaced by a Dresidue, as observed 
in the consensus sequence, in order to increase the solubility 
of the resulting pentapeptide P5 (QLDLF). Although its affin 
ity for the fring is low, it was increased by 10 fold upon 
acetylation (table 1, compare P5 and P6), thus providing a 
good compromise between interaction efficiency and ligand 
S17C. 
US 9,133,240 B2 
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TABL E 1. 
Influence of the C-terminal tripeptide sequence 
and effect of N-terminal acetylation on the 
16 
TABLE 2 
Statistics on Data Collection and Refinement (related to FIG. 5). 
Beta-P14 Beta-P6 Beta-P12 
interaction of peptide with the E. coli 3 5 Structure (PDB 3Q4L) (PDB 3Q4J) (PDB 3O4K) 
clamp, as measured by SPR experiments. 
Data Collection 
Se- ICso ki -l AG (Kcal/ Seq Id Space Group P1 P1 P1 
# quence (uM) (10 M-1) mol) No : Unit cell a (A) 34.84 35.09 36.25 
10 b (A) 79.57 132.87 8O 
PoIW O29 4.7 -9. O9 c (A) 81.64 137.27 82.18 
C. () 65.28 62.73 66.15 
P1 RQLVLGL 8.85 O. 15 -7. O6 1. B (-) 75.26 88.51 74.94 
Y () 82.22 89.77 82.03 
Beamline ID29, ESRF XO6SASLS ID14-4, ESRF 
P2 ROLVLL 21.53 O. OO 63 - 654 2 15 Wavelength (A) O.97623 O.915694 O.9794 
Resolution limits (A) 39.2-1.95 29.5-2.3 19.9-26 
P3 RQLWLF 8, 62 O. 15 -7. O4 3 high resolution shell 2.0-1.95 2.35-2.3 2.65-26 
Reflections: 
P4 RQLVFL 256 2. 2. 4. measured 221062 296785 42708 
2O unique S4138 96508 22982 
P5 QLDLF 12. 44 O. 11 - 6.87 5 Completeness (%) 96.3 (93.8)* 98.6 (97.9)* 91.9 (60.5)* 
merge 0.06 (0.72)* 0.05 (0.36)* 0.067 (0.11)* 
fo 13 (1.9)* 22.6 (3.6)* 8.7 (4.0)* 
P6 AcQLDLF 1. 12 1.2 -8.22 6 Refinement 
2: not determined. Reflections R/R. 54134/2750 96493/7742 22979/1160 
Ki = (1 + K IC 25 R. (%) 20.1 21.6 25.9 i = (1 + KB) / IC50. R. (%) 23.2 2SO 30.6 
AG = -RT ln Ki. Protein atoms 5579 17085 54.71 
PolIV: E coli DNA polymerase IV. Ligand atoms 106 196 103 
Water molecules 299 357 129 
A. B factor (A 1.2.2. Crystal Structure of the P6-f Ring Complex. 30 Average B factor (A) 
The P6 peptide (AcOLDLF, SEQID No.: 6) co-crystallized Protein 33.3 52.1 3O4 
ith th diti imil to th 1 Ligand 39.4 66.5 27.1 
witn ine B. r1ng 1n cond111ons S1m1lar to Unose prev1ously Water 40.1 445 27.6 
described' but the cell parameters lead to a V value of 7.8, R.m.S.d. bond length O.O1 O.OO9 O.OO8 
which corresponds to the presence of 3 dimers per asymmet- (A) 
R.m.S.d. angles length 1.13 1.15 1.11 
ric unit (Table 2). This structure was solved by molecular 35 () 
replacement at 2.3 A resolution, using our previously deter 
mined structure (PDB 1OK7). The Superposition of main Values in parentheses correspond to high resolution shell in data collections, 
5% of the reflections were set aside for an Rfree test before initiating any refinement 
chain atoms of each ring to the model led to rmsd values 
ranging from 0.70 A to 1.06 A, underlining the close struc- 40 The atomic coordinates of the peptide and the peptide 
tural similarity of each dimer. Each monomer of the three 
rings binds a peptide, and all ligands adopt a similar confor 
mation in all six hydrophobic pockets, as indicated by armsd 
value ranging between 0.25 A to 0.51 A. 
binding site of the B clamp (residues <5 A from the ligand)are 
disclosed in the followingTable 3. The other residues have the 
same positions as in the previously determined structure 
NE 
CZ 
NH1 
NH2 
CG 
CD1 
CD2 
(PDB 1OK7) also described in U.S. Pat. No. 7,635,583. 
TABLE 3 
Atomic coordinates of P6 residues and of the residues involved in the binding of P6 
to the B clamp, in the crystal of P6 peptide co-crystallized with the Bring. 
ARG B S2 10.195 -25.903 12.978 OO 60.02 N 
ARG B 52 9.832 -25.010 13.891 OO 70.75 C 
ARG B S2 10.045 -23.710 13.686 OO 51.13 N1 
ARG B 52 9.228 -25.4O2 15.004 OO 66.21 N 
ARG B 52 
LEU B 55 6.034 -25.353 10.SS1 OO 37.71 C 
LEU B 55 6.887 -24.861 11.676 OO 37.67 C 
LEU B 55 4.805 -25.976 11.115 OO 31.46 C 
LEU B 55 
THR B 72 1710 -23.748. 14.242 OO 31.63 C 
THR B 72 2.028 -25.084 13.527 OO 27.98 C 
THR B 72 2.665 -23.450 15.241 OO 32.30 O 
ASP B 73 6.157 -21.665 14.133 OO 35.44 C 
GLY B 74 S.672 - 22.SS1 14.996 OO 34.81 N 
GLY B 74 6.511 -23.182 16.011 OO 35.62 C 
GLY B 74 6.492 -22.492 17359 OO 39.39 C 
GLY B 74 6.970 -23.064 18344 OO 39.92 O 
HIS B 75 5.986 -21.242 17.411 OO 34.18 N 
HIS B 75 S.900 -20.479 18.6SO OO 33.72 C 
HIS B 75 4.476 -20.329 19.088 OO 35.43 C 
HIS B 75 4.175 -20.368. 20.282 OO 34.79 O 
HIS B 75 6.562 -19.119 18.513 OO 36.12 C 
ATOM 1 
ATOM 2 
ATOM 3 
ATOM 4 
TER 5 
ATOM 6 
ATOM 7 
ATOM 8 
TER 9 
ATOM 10 
ATOM 11 
ATOM 12 
ATOM 13 
ATOM 14 
ATOM 15 
ATOM 16 
ATOM 17 
ATOM 18 
ATOM 19 
ATOM 2O 
ATOM 21 
ATOM 22 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TER 
A 
A 
A 
TOM 
TOM 
TOM 
TER 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TER 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TER 
A 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TER 
A 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TER 
A 
A 
TOM 
TOM 
TER 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
to the B clamp, in the crysta 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
S4 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
8O 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
CG 
CD2 
ND1 
CE1 
NE2 
N 
CA 
C 
O 
N 
CA 
CB 
CG 
CD1 
CB 
CG 
CD 
CD1 
CE1 
CA 
CB 
CG 
ND2 
CB 
CG 
CD2 
CE2 
CZ 
OH 
CA 
CB 
OG 
E 
E 
E 
E 
E 
RO 
AL 
AL 
AL 
VAL 
VAL 
GLY 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
TY 
TY 
TY 
TY 
TY 
TY 
TY 
SER 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
SER 
SER 
SER 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
PRO 
PRO 
PRO 
PRO 
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TABLE 3-continued 
Atomic coordinates of P6 residues and of the residues involved in the binding of P6 
of P6 peptide co-crystallized with the Bring. 
75 7.984 -19.194 18.096 1.OO 4164 
75 9.032 -19.835 18.668 1.OO 44.85 
75 8.394 -18.617 16.936 1.OO 45.18 
75 9.678 -18.899 16.829 1.OO 45.14 
7S 10.115 -19.589 17.878 1.OO 45.20 
76 3.593 -20.133 18.121 OO 31.08 
76 2.181 -19986 18.371 OO 29.68 
76 1413 -20.789 17.353 1.OO 32.45 
76 1918 -21.053 16.262 100 3286 
77 O.240 -21.239 17.733 1.OO 27.89 
77 -0.619 -22.029 16.87S 1.OO 27.83 
77 -0.579 -23.523 17.307 1.OO 27.38 
77 - 1466 -24.512 16.510 1.OO 31.18 
77 -0.745 -25.845 16.280 1.OO 30.87 
77 
242 3.262 -29.933 14.OO3 1.OO 42.35 
242 3.185 -28.774 13.11.2 1.OO 45.82 
242 3.325 - 29.32O 11.74S 1.OO 40.86 
242 
247 -0.058 -27.602 22.929 1.OO 52.04 
247 O.470 -28.149 19.728 1.OO SO.73 
247 O.S74 -26.6SS 20.015 1.OO SO.SO 
247 1641 -28.626 18.875 1.OO 51.23 
247 
318 S474 - 15.393 28.086 1.OO 28.75 
319 S.344 - 13.22S 27.583 1.OO 24.23 
319 4.851 - 13.489 26.241 OO 24.99 
319 5.356 - 12.468 25.290 1.OO 30.49 
319 S.S91 - 11.324 25.669 1.OO 32.74 
319 3.310 -13.478 26.174 1.OO 27.25 
319 2.640 - 14.732 26.670 1.OO 28.63 
319 2.741 -15.919 25.957 1.OO 30.47 
319 2.128 -17.094 26.424 1.OO 316O 
32O 5468 - 12.865 24.025 1.OO 26.27 
32O S.720 - 11.953 22.949 1.OO 26.75 
32O 4.315 -11.306 22.76O 1.OO 28.81 
32O 3.351 - 11.990 22.409 1.OO 25.74 
32O 6.143 - 12.740 21.690 1.OO 31.09 
32O 6.252 - 11.902. 20.458 1.OO 38.50 
32O 7.226 -12.202 19631 OO 36.32 
32O 
323 2.398 - 14.188. 20.062 1.OO 29.74 
323 3.671 -14.541. 19.312 1.OO 34.89 
323 4.613 -15.405 19.867 1.OO 36.98 
323 S.769 -15.758 19.176 1.OO 38.52 
323 S.978 - 15.28O 17.899 1.OO 45.00 
323 7.102 - 15.660 17.220 1.OO 51.04 
323 
343 6.499 -19.652 31.418 1.OO 42.19 
344 7.142 - 22.358 31.029 1.OO 30.95 
344 6.382 -23.22S 30.039 1.OO 37.16 
344 6.960 -23.833 29.13S 1.OO 38.77 
344 8.406 -23.O37 31.63O 1.OO 34.02 
344 9.318 -22.OO2 32.284 1.OO 33.14 
344 
346 1.690 -23. SOO 25.23O 1.OO 34.25 
346 O.915 -24.661. 25.493 1.OO 39.01 
346 
360 -0.613 -20.918 21.452 1.OO 27.37 
360 -0.111 -20.800 20.340 1.OO 24.84 
360 -1.624 -23.300 21.499 1.OO 27.65 
360 -0.575 -23.807 22.494 1.OO 27.63 
361 1982 - 19886 23.474 1.OO 27.90 
361 1873 - 16.988 22.SS6 1.OO 22.99 
362 3.180 -2O112 23.023 1.OO 28.61 
362 4.274 -20.561 23.871 OO 28.56 
362 4.839 -19.321 24.53O 1.OO 31.58 
362 S.O39 -18.292 23.87O 1.OO 29.49 
362 5.340 -21.3O2 23.049 1.OO 3141 
362 6.222 -22.193 23.888 1.OO 35.60 
362 S.377 -23.603 24.664 1.OO 38.96 
362 6.619 -24.06O 25.847 1.OO 34.70 
363 5.071 -19.362 25.842 1.OO 29.24 
363 S. 609 -18.178 26.510 1.OO 28.99 
363 7.074 - 17892 26.226 1.OO 33.83 
363 7.743 -18.614 25.456 1.OO 33.34 
363 S.341 - 18.479 27.991 OO 30.94 99 PRO 
o 
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Atomic coordinates of P6 residues and of the residues involved in the 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
ETATM 
ETATM 
ETATM 
ETATM 
ETATM 
ETATM 
ETATM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
A TOM 
TER 
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TABLE 3-continued 
o the B clamp, in the crystal of P6 peptide co-crystallized with the Bring. 
OO 
O1 
O2 
O3 
O4 
05 
O6 
O7 
O8 
09 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
2O 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
S4 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
CG 
CD 
N 
CA 
C 
O 
CB 
CG 
SD 
CE 
N 
CA 
C 
O 
CB 
CG 
3 
A. 
CD1 
CD2 
OD1 
OD2 
CA 
o 
CB 
CG 
CD1 
CD2 
CA 
B 
CG 
CD1 
CD2 
CE1 
CE2 
CZ 
OXT 
PRO 
PRO 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
HOH 
HOH 
HOH 
H 
H 
H 
H 
H 
H 
H 
H 
363 
363 
364 
364 
364 
364 
364 
364 
364 
364 
365 
365 
365 
365 
365 
365 
365 
365 
365 
365 
365 
365 
384 
407 
465 
466 
69 
69 
69 
70 
70 
70 
70 
70 
70 
70 
70 
70 
71 
71 
71 
71 
71 
71 
71 
71 
72 
72 
72 
72 
72 
72 
72 
72 
73 
73 
73 
73 
73 
73 
73 
73 
74 
74 
74 
74 
74 
74 
74 
74 
74 
74 
74 
74 
74 
5.412 
4870 
7.545 
8.945 
9.SO2 
8.772 
9.118 
8.757 
8.724 
O.S28 
0.767 
1463 
1620 
2.039 
2.812 
3.354 
2.589 
3.073 
2.957 
3.409 
2.398 
8.833 
O.652 
2.648 
3.941 
2:190 
1809 
3.141 
1.778 
O.826 
1.026 
1987 
O.668 
9.SO3 
8.133 
7.769 
7.418 
10.077 
10.074 
9.337 
8.603 
9.507 
10.264 
9.369 
11.512 
9.557 
8.966 
7.805 
7.847 
10.057 
10.805 
11.558 
10.576 
6.766 
5.598 
S.949 
S.343 
4.487 
3.484 
2.433 
2.807 
6.897 
7.378 
8.752 
9.100 
6.340 
5.819 
6.5O2 
4.661 
6.047 
4230 
4.918 
9.469 
28.091 
26.798 
26.784 
26.731 
28.124 
29.12O 
26.403 
25.034 
24.682 
24.937 
28.190 
29.447 
30.209 
29.621 
29.173 
30.335 
30.62O 
29.817 
30.161 
29.355 
31.318 
20.130 
21.066 
22.219 
23.870 
25.287 
25.955 
25.924 
24.012 
23.246 
23.243 
22.644 
21816 
21.019 
21.688 
22.096 
21.901 
23.889 
23.930 
22.690 
22.008 
25.254 
26.5SO 
27.773 
26.736 
22.379 
21.213 
21.558 
22.589 
20.397 
19.472 
19986 
18.231 
20.694 
20.839 
20.585 
21.1.89 
binding of P6 
OO 35.37 
OO 31.25 
OO 29.71 
OO 30.02 
OO 40.88 
OO 40.62 
OO 30.48 
OO 32.54 
OO 35.07 
OO 31.33 
OO 42.29 
OO 44.24 
OO 47.68 
OO 46.53 
OO 49.79 
OO 61.58 
OO 75.54 
OO 90.27 
OO 100.27 
OO 79.16 
OO 86.12 
OO 33.25 
OO 31.86 
OO 36.65 
OO 26.96 
OO 47.99 
OO 46.88 
OO 48.05 
OO 43.64 
OO 42.45 
OO 48.79 
OO 49.83 
OO 43.26 
OO 48.43 
OO 51.59 
OO 32.22 
OO 38.15 
OO 44.09 
OO 42.82 
OO 47.21 
OO 46.65 
OO 42.99 
OO 48.52 
OO 48.02 
OO S3.09 
OO 45.35 
OO 45.33 
OO 46.72 
OO 44.98 
OO 47.71 
OO 73.93 
OO 75.90 
OO 87.47 
OO 44.17 
OO 44.82 
OO 49.95 
OO 49.17 
OO 44.08 
OO 45.47 
OO 45.34 
OO 38.54 
OO 47.70 
OO 48.65 
OO 75.49 
OO 77.08 
OO 49.99 
OO SO.87 
OO 52.73 
OO 52.30 
OO 52.86 
OO 53.68 
OO 51.51 
OO 100.17 1 
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TABLE 3-continued 
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Atomic coordinates of P6 residues and of the residues involved in the binding of P6 
to the B clamp, in the crystal of P6 peptide co-crystallized with the Bring. 
HETATM 
END 
175 O HOH H 86 5.592 - 15.725 23.553 
A free energy decomposition analysis (see Material and 
Methods for details) of this complex was performed (FIG. 
2B) and the most important interactions are similar to the 
initial complex 1 OK7, as expected. The canonical sequence 
LF advantageously replaces the LGL sequence in C-ter of the 
peptide (FIG. 2B). The P6 peptide acetyl group also forms 
two hydrogen bonds with the NC. of residues Res and Lee of 
the B monomer which probably account for the 10 fold 
increase in stability of the P6 peptide as compared to P5 
(Table 1). Despite its reduced size, the P6 peptide therefore 
has an increased affinity for the f-clamp with respect to the 
original peptide P1. 
1.2.3. Design of Non-Natural Peptides Ligands with 
Increased Binding Affinity. 
P6 was further used as a lead to introduce modifications 
aimed at increasing the affinity of the ligand for the 3 clamp. 
Because the natural ligand binds to the pocket essentially 
through hydrophobic interactions, the aim was to extend the 
network of such interactions. A first set of modifications 
concerned position 2, where the leucine residue was replaced 
by a cyclohexyl-L-alanyl group (Cha) (P7, table 4 and table 
7). An initial modeling analysis, using programs MCSS and 
SEED, indicated that this modification provides a Van der 
Waals energy contribution two-fold higher than that with the 
natural L residue, and is the most efficient group tested 
(Table 4). It also results in a 6 fold increase in the interaction, 
as measured by SPR (Table 4 and Table 7, compare P6 and 
P7). Attempts to increase the side chain length resulted in a 
drastic reduction of the affinity (Table 4 and Table 7, P8) 
while other modifications like homoleucyl (hLeu) or neopen 
tylglycyl (NptGly, also called tertiomethylbutylglycine, 
tBMG) did not yield any gain in affinity (Table 4 and Table 7. 
P9 and P10), probably indicating that the area available for an 
efficient interaction is limited. 
TABLE 4. 
Effect of site-specific modifications of 
the second residue on the interaction 
of peotide with the E. coli clamp. 
sequence ICso (uM) SEQ ID No: 
P6 AcQLDLF 1. 12 6 
p7 Ac Q ChaDLF O. 17 7 
P8 Ac Q hoha DLF 82.8 8 
P9 AC Q hLieu. DLF O. 74 9 
P10 AC Q NptCly DLF O. 99 1O 
Cha: Cyclohexylalanine, 
hCha: homocyclohexylalanine, 
hLieu: homoleucine, 
NptGly: neopentylglycyl. 
A second set of similar modifications was introduced at 
position La, but no increase in affinity was observed as com 
pared to P7 (Table 5). 
1.OO 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
33.16 O 
TABLE 5 
Effect of site-specific modifications 
of the L4, residue on the interaction 
of peotide with the E. coli clamp. 
sequence ICso (uM) SEQ ID No: 
P6 AcQLDLF 1. 12 6 
p7 Ac Q Cha DLF O. 17 7 
P16 Ac Q Cha D hLieu. F O. 23 16 
P17 Ac Q Cha D Cha F O 31 17 
P18 Ac Q Cha D hCha F O. 72 18 
P19 Ac Q ChaD NptCly F 5, 63 19 
Finally, several modifications were introduced on the ter 
minal phenylalanine benzyl ring (Table 6). The binding affin 
ity was found to increase significantly with the size of the ring 
substituent (p-methyl-p-chloro-p-bromo-3,4-dichloro)(see 
P11, P12, P13, and P14, respectively). An ICs value of 70 nM 
was measured for the 3,4-dichlorophenylalanine containing 
peptide (P14), which represent a 15, 115 and 4 fold increase 
as compared to P6, P1 and the full PolIV enzyme, respec 
tively (Table 6 and Table 7). To the contrary, replacement of 
the terminal phenylalanine by a cyclohexyl-L-alanyl group 
(Cha), a tryptophan or a 2-amino-tetradecanoic acid (Atda) 
(P20, P21 and P22, Table 6) led to a decreased affinity. 
TABLE 6 
Effect of modifications on the 
terminal phenylalanine benzyl ring 
on the interaction of peptide with 
the E. coli clamp. 
sequence ICso (uM) SEO ID No: 
P6 AcQLDLF 1. 12 6 
P11 Ac-Q Cha DL plMeF O.26 11 
P12 Ac-Q Cha DL pClF O. 16 12 
P13 Ac-Q Cha DL pBrF O 1 O 13 
P14. Ac- Q Cha DL diClF O. Of2 14 
P2O Ac- Q Cha DL Cha O. 41 2O 
P21 Ac- Q Cha DLW O. 64 21 
P22 Ac-Q Cha DL. Atda 3.72 22 
The interactions of the various peptides with the Bring 
were also evaluated using a polymerase competition assay 
where primer elongation performed by the polIV DNA poly 
merase is challenged by various concentrations of the pep 
tides to be tested'’ While the B independent activity of the 
polymerase is insensitive to the peptides, indicating that they 
have no direct effect on the enzyme activity, the B dependent 
elongation activity is differentially inhibited depending on 
US 9,133,240 B2 
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the affinity of the peptide for its target (FIG. 4). A quantitative 
analysis of the biochemical assays is shown in FIG. 7. 
Although this approach is less sensitive than SPR, a good 
correlation is observed between the two methods (FIG. 4). 
TABLE F 
Influence of the C-terminal tripeptide sequence 
and effect of site specific modifications on 
the interaction of peptide with the E. coli B 
clamp, as measured by SPR experiments. 
Ki AG Seq 
Se- ICso (106 (Kcal/ Id 
quence (uM) MI) mol) No : 
PoIW O29 4.7 -9. O9 
P1 RQLVLGL 8.85 O. 15 -7. O6 1. 
P2 RQLWLL 21.53 O. OO 63 - 654 2 
P3 RQLWLF 8, 62 O. 15 -7. O4 3 
P4 RQLVFL 256 2. 2. 4. 
P5 QLDLF 12. 44 O. 11 - 6.87 5 
P6 AcQLDLF 1. 12 1.2 -8.22 6 
p7 Ac Q ChaDLF O. 17 8. O1 -9. 42 7 
P8 Ac Q hoha DLF 82.8 16. 4 -5 74 8 
P9 Ac Q Hol. DLF O.74 1.84 -8.54 9 
P10 Ac Q Nptdly DLF O.99 1.36 -8.36 1O 
P11 Ac-Q Cha DL plMeF O.26 8.43 -9. 44 11 
P12 Ac-Q Cha DL pClF O. 16 13.7 -973 12 
P13 Ac-Q Cha DL pBrF O. O.9613. 49 -971 13 
P14. Ac- Q Cha DL diClF O. O.7717 -985 14 
2: not determined. 
Ki = (1 + KBI) / IC50. 
AG = -RT ln Ki. 
PolIV: E coli DNA polymerase IV. 
The following table 8 presents the analytical data concerning 
the most relevant peptides described in this study. 
TABLE 8 
Sequence and analytical data of C-terminal 
peptides of the E. coli DNA polymerase IV 
and analogues (related to FIG. 1 and 
table 7). 
PU- MS 
HPLC RITY FOUND SEO 
Pep- tR & CALC. M + ID 
tide compound (min) HPLC MASS H" No: 
P1 H-Arg-Gln-Leu-Val- 1.97 98.2 799. Of 99.9 1. 
Lieu-Gly-Leu-OH 
P2 H-Arg-Gln-Leu-Val- 1. SO 93 ... O 74. O. 5741.9 2 
Leu-Leu-OH 
P3 H-Arg-Gln-Leu-Val- 2.13 92.1 774. 5775.8 3 
Leu-Phe-OH 
P4 H-Arg-Gln-Leu-Val- 2. O2 92.5 774. 5775.5 4. 
Phe-Leu-OH 
P5 H-Gln-Leu-Asp-Leu- 2.55 9 O 634 3634.8 5 
Phe-OH 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
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TABLE 8- continued 
Sequence and analytical data of C-terminal 
peptides of the E. coli DNA polymerase IV 
and analogues (related to FIG. 1 and 
table 7). 
PU- MS 
HPLC RITY FOUND SEO 
Pep- tR & CALC. M + ID 
tide compound (min) HPLC MASS H'l No: 
P6 Ac-Gln-Leu-Asp-Leu- 13.25 92.5 676.3677.3 6 
Phe-OH 
p7 Ac-Gln-Cha-Asp-Leu- 15.12 95 716.8717.7 7 
Phe-OH 
P8 Ac-Gln-hCha-Asp-Leu-16. 23 50.93 730.8731.4 8 
Phe-OH 
P9 Ac-Gln-Hol-Asp-Leu- 14.23 90 69 O. 8691. O 9 
Phe-OH 
P1 O AC-Gln-NptGly-Asp- 3.99 94 7 O2.86.917 10 
Leu-Phe-OH 
P11 Ac-Gln-Cha-Asp-Leu- 15.88 97 716. 4732.7 11 
pMePhe-OH 
P12 AC-Gln-Cha-Asp-Leu- 16.27 93 736.3752.7 12 
pClPhe-OH 
P13 Ac-Gln-Cha-Asp-Leu- 16.45 95 794 3799.8 13 
pBrPhe-OH 
P14 AC-Gln-Cha-Asp-Leu- 17. 18 91 784 .3786.9 14 
(3, 4-di-Cl) Phe-OH 
Cha: beta-cyclohexyl-L-alanyl; 
hCha: L-homoCha; 
Hol: L-homoleucyl; 
NptGly: neopentylglycyl; 
pMePhe: 4-methyl-L-phenylalanyl; 
pClPhe: 4-chloro-L-phenylalanyl; 
pBrPhe: 4-bromo-L-phenylalanyl; 
(3, 4-di-Cl) Phe: 3, 4-dichloro-L-phenylalanyl 
1.2.4. Crystal Structure of the Modified Peptides B Ring 
Complexes. 
Peptides P12 and P14 were co-crystallized with the Bring. 
The structures were solved by molecular replacement at 2.6 A 
and 1.95 A resolution respectively, using the 10K7 structure 
as a search model. As for the previous P6-f complex, both 
complexes crystallized in space group P1 but with one ring 
per asymmetric unit (Table 3). Each monomer of the rings 
binds a peptide, and both ligands adopt a similar configura 
tion (rmsd=0.70 A and 0.78 A for the peptides atoms of P12 
and P14, respectively), indicating that the modified peptides 
essentially adopt the same conformation and location in the 
binding pocket. The Chamoiety is located at the same posi 
tion as the L residue of P6 but extends its interaction further 
within a hydrophobic pocket shaped by the P. V. M. 
and Rs B residues (FIG.5A) and interacts with the last three 
residues. These extra interactions probably account for the 
increased affinity of P7 as compared to P6 (table 1). Addi 
tionally, the No. of this modified residue interacts with the 
CO-O of Ps. The p-chloro and 3,4-dichloro F residues of 
P12 and P14 are almost superimposed (FIG. 5B) and interact 
with 3 residues T, L7, and V47. The chlorine atom in 
meta position in P14 establishes an halogen bond with the 
hydroxyl oxygen of T-72, with contact distance and angle in 
good agreement with previously published data (d=3.17 A 
and 0–148.71)'. In contrast, the parachlorine atoms of both 
P12 and P14 do not establish such type of interaction because 
25 
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the distances with adjacent oxygenatoms off residues are too 
large. 
The atomic coordinates P12 and P14, co-crystalized with 
the B clamp, are disclosed in the following Tables 9 and 10. 
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These tables indicate the atomic coordinates of the peptides 
and of the binding site of the ?clamp (residues.<5A from the 
ligand). The other residues have the same positions as in the 
previously determined structure (PDB 1OK7) 
also described in U.S. Pat. No. 7,635,583. 
TABLE 9 
Atomic coordinates of P12 residues and of the residues involved in the binding of P12 
to the B clamp, in the crystal of P12 peptide co-crystallized with the Bring. 
A TOM 
TER 
A 
TER 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
TER 
A 
TER 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TER 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TER 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
NH1 ARG. A 52 - 13.878 13.827 24.977 OO 41.13 N1 
ARG. A 52 
CD2 LEU A SS -9.376 16.306 22.697 OO 33.78 C 
LEU A 55 
CB THR A 72 -S.S79 13.66O 24.332 OO 10.80 C 
CG2 THR A 72 -6.162. 15.062 24.379 OO 3.00 C 
OG1 THR A 72 -6.396 12.784. 25.111 OO 11.87 O 
THR A 72 
N GLY A 74 -9.37S 11662 24.270 OO 22.35 N 
CA GLY A 74 -10.197 11.573 25.471 OO 21.94 C 
C GLY A 74 -9.904 10.341 26.321 OO 26.11 C 
O GLY A 74 -10.187 10.331 27.522 OO 24.70 O 
N HIS A 7S -9.341 9.286 25.699 OO 23.67 N 
CA HIS A 7S -9.001 8.008 26.347 OO 23.91 C 
C HIS A 7S -7.479 7.869 26.584 OO 24.57 C 
O HIS A 75 - 7.046 7.395 27.635 OO 24.56 O 
CB HIS A 7S -9.546 6.822 25.519 OO 25.86 C 
CG HIS A 75 - 10.971 7.OOS 25.08O OO 30.11 C 
CD2 HIS A 75 - 11.486 7.14O 23.838 OO 32.30 C 
ND1 HIS A 75 - 12.OOS 7.08.2 25.997 OO 32.23 N 
CE1 HIS A 75 - 13.107 7.245 2S288 OO 31.59 C 
NE2 HIS A 75 - 12.845 7.286 23.98S OO 32.09 N 
N ARG. A 76 -6.68S 8.29O 25.610 OO 18.69 N 
CA ARG A 76 -S.234 8.264. 25.702 OO 18.59 C 
C ARG. A 76 -4.604 9.609 25.304 OO 24.08 C 
O ARG. A 76 -5.276 10.463 24.713 OO 23.83 O 
N LEU A 77 -3.347 9.832 25.715 OO 1954 N. 
CA LEU A 77 -2.653 11.088 25.503 OO 18.04 C 
CB LEU A 77 -2.873 11.987 26.745 OO 17.92 C 
CG LEU A 77 -1963 13.211 26.971 OO 21.84 C 
CD1 LEU A 77 -2.328 14347 26.066 OO 21.30 C 
CD2 LEU A 77 -2.004 13.663. 28.416 OO 22.36 C 
LEU A 77 
CA PRO A 242 -8.284 20.266 27.211 OO 10.30 C 
C PRO A 242 -7.012 20.416 28.076 OO 16.74 C 
CB PRO A 242 -8.798. 18.838 27.188 OO 11.44 C 
CG PRO A 242 -8.164 18.255 25.944 OO 16.16 C 
CD PRO A 242 -8.332 19.361 24.955 OO 11.62 C 
N ASP A 243 -7.224 20.463 29.391 OO 1424 N 
CA. ASP A 243 -6.222 20.608 30.438 OO 14.52 C 
C ASP A 243 -5.454. 19.282 30.6.18 OO 21.86 C 
O ASP A 243 -5842 18424 31.416 OO 25.37 O 
N TYR A 244 -4471. 19.055 29.748 OO 15.9S N 
CA TYR A 244 -3.688 17.827 29.764 OO 15.04 C 
CB TYR A 244 -2900 17.645 28.437 OO 14.90 C 
TYR A 244 
NH1 ARG. A 246 -9.401 15.913 36.324 OO 21.44 N1 
CB VAL A 247 -4.905 13.902 32.710 OO 29.59 C 
CG1 VAL A 247 -S.480 12.SS1 33.104 OO 29.67 C 
CG2 VAL A 247 -6.O24 14.870 32.343 OO 29.06 C 
VAL A 247 
O PHE A 278 -11396 -2.943 23.858 OO 27.53 O 
PHE A 278 
N ASN A 320 - 7.095 -1.216 26.969 OO 26.OON 
CB ASN A 320 -8.OSO -0.27S 24.887 OO 19.44 C 
CG ASN A 32O -8.114 -0.289 23.378 OO 25.87 C 
ND2 ASN A 320 -9.197 0.247 22.826 OO 19.30N 
OD1 ASN A 320 -7.179 -0.699 22.685 OO 16.42 O 
ASN A 320 
CD2 TYR A 323 - 6.890 3.229 24.491 OO 20.56 C 
CE2 TYR A 323 -8.089 3.767 24.028 OO 21.88 C 
CZ TYR A 323 -8.254 4.01S 22675 OO 3 O.S.1 C 
OH TYR A 323 -9.422 4.548 22199 OO 34.44 O 
TYR A 323 
O SER A 343 -8.42O 0.538. 36.986 OO 43.3S O 
CA VAL A 344 -9.412 2.967 38.022 OO 37.68 C 
C VAL A 344 -8.749 4.286 37.541 OO 39.37 C 
O VAL A 344 -9.43O 5.162 37.004 OO 37.60 O 
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TABLE 9-continued 
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Atomic coordinates of P12 residues and of the residues involved in the binding of P12 
to the B clamp, in the crystal of P12 peptide co-crystallized with the Bring. 
ATOM 
ATOM 
TER 
ATOM 
TER 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
TOM 
TOM 
TO M 
TOM 
ET AT 
A TO M 
TOM 
TOM 
TOM 
TOM 
TOM 
E T AT M 
s : 
A TO M 
A TO M 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
8O 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
OO 
O1 
O2 
O3 
O4 
05 
O6 
O7 
O8 
09 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
2C 
21 
22 
23 
24 
25 
26 
27 
28 
29 
3C 
31 
32 
33 
34 
35 
36 
37 
38 
39 
4C 
41 
42 
43 
44 
45 
CB 
O 
CG1 
C 
&AO 
: 
3 
A. 
CD1 
CD2 
CE1 
CE2 
CZ 
N 
CA 
C 
O 
CB 
CG 
OD1 
OD2 
VAL 
VAL 
VAL 
SER 
SER 
VAL 
VAL 
VAL 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
PRO 
PRO 
PRO 
PRO 
PRO 
PRO 
PRO 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
HOH 
HOH 
HOH 
N 
LN 
C 
344 
344 
344 
346 
346 
360 
360 
360 
362 
362 
362 
362 
362 
362 
362 
362 
363 
363 
363 
363 
363 
363 
363 
364 
364 
364 
364 
364 
364 
364 
365 
365 
365 
365 
365 
365 
365 
365 
365 
365 
365 
397 
422 
433 
24 
367 
367 
367 
368 
368 
368 
368 
368 
368 
368 
368 
368 
368 
369 
369 
369 
369 
369 
369 
369 
369 
369 
369 
369 
370 
370 
370 
370 
370 
370 
370 
370 
-10.716 
-11.660 
-4.248 
-2.861 
-2.051 
-5.771 
-6.824 
-7.277 
-7.461 
-7.994 
-8.871 
-8.107 
-9.291 
-7.464 
-7.885 
-9.367 
-10.161 
-7.534 
-7.733 
-7.288 
-973S 
-11.116 
-11510 
-11392 
-10.591 
-10.644 
-12.3SS 
-12.802 
-13.345 
- 13.715 
-14.777 
-14987 
-16.323 
-16.385 
-17.177 
-17.980 
-17.162 
-12.948 
3.216 
2.025 
7.581 
8.288 
9.515 
5.847 
S. 610 
4.123 
3.593 
6.560 
6.790 
7.741 
7.371 
3.423 
2.016 
1.784 
2.723 
1.508 
2.646 
3.852 
0.505 
O.063 
-O.892 
-0.494 
-1.704 
-1982 
-2.53S 
-O.893 
-1.727 
-3. 627 
-1.280 
-O.808 
-0.093 
O.668 
1.718 
2.151 
2.350 
-0.572 
S.096 
1912 
1.716 
O.704 
1136 
-0.454 
1401 
2.699 
3.790 
4.442 
3.398 
4.252 
3.491 
3.893 
2.411 
4.147 
5.508 
6.300 
5.719 
S.S16 
4.8OO 
3.659 
4.431 
2.854 
3.799 
2.730 
7.629 
8.830 
9.729 
9.697 
8.546 
8.727 
8.114 
9.287 
38.843 
38.749 
33.672 
27.992 
31.551 
29.897 
30.866 
30.792 
29.689 
30.587 
31.773 
33.104 
34.427 
31.935 
31.872 
31.553 
31.445 
33.276 
34.141 
33.338 
31.409 
31.233 
32.363 
29.827 
29.437 
27.634 
27.415 
32.770 
33.857 
32.448 
34190 
35.628 
35.795 
37.050 
37.255 
36.291 
38.424 
24.569 
38.996 
27.730 
24.238 
29.591 
30.667 
29.524 
28.359 
28.412 
29.559 
29.488 
26.993 
26.986 
27.350 
28.463 
26.809 
3O488 
30.964 
29.995 
29.263 
32.374 
33.632 
34.076 
33.398 
35.208 
34.618 
35.276 
29.488 
30.301 
31.12O 
32.347 
30.909 
29.752 
29.765 
28.668 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
41.47 C 
41.11 C 
36.35 C 
21.29 O 
22.57 C 
24.O1 N 
25.90 C 
30.54 C 
29.30 O 
29.26 C 
34.65 C 
40.06 S 
36.64 C 
28.36 N 
27.57 C 
32.79 C 
30.76 O 
29.22 C 
33.99 C 
30.19 C 
33.12 N 
34.28 C 
38.91 C 
37.35 C 
42.38 C 
48.21 s 
45.40 C 
36.16 N 
S4.18 C 
15.77 O 
54.40 C 
61.81 C 
67.50 C 
70.43 N 
69.73 C 
47.59 N1 
45.96 N 
24.99 O 
47.81 O 
9.25 O 
3O48 O 
35.56 C 
30.52 O 
29.87 C 
30.56 N. 
25.45 C 
32.24 C 
32.94 O 
29.55 C 
29.78 C 
23.65 C 
24. SON 
27.24 O 
28.64 N 
29.77 C 
30.06 C 
32.57 O 
29.41 C 
27.38 C 
26.63 C 
29.06 C 
26.40 C 
36.93 C 
30.08 C 
34.94 N 
34.00 C 
30.52 C 
25.64 O 
38.94 C 
40.34 C 
59.35 O 
3O.OS O1 
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TABLE 9-continued 
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Atomic coordinates of P12 residues and of the residues involved in the binding of P12 
to the B clamp, in the crystal of P12 peptide co-crystallized with the Bring. 
ATOM 46 N LEU C 371 -1O.S60 10.539 30.269 OO 32.14 N 
ATOM 47 CA LEU C 371 -9.624 11.571 30.769 OO 33.35 C 
ATOM 48 C LEU C 371 -10.269 12.914 31.093 OO 36.56 C 
ATOM 49 O LEU C 371 -9.703 13.671 31.882 OO 38.88 O 
ATOM SO CB LEU C 371 -8.46S 11.790 29.754 OO 29.71 C 
ATOM S1 CG LEU C 371 - 7.489 10.663. 29.542 OO 32.92 C 
ATOM S2 CD1 LEU C 371 -6.748 10.753 28.242 OO 21.26 C 
ATOM S3 CD2 LEU C 371 -6.637 10.343 30.752 OO 23.07 C 
TER S4 LEU C 371 
HETATM 55 N. 200 C 372 -11.514 13.352 30.399 OO 31.07 N 
HETATM S6 CA 200 C 372 - 12.085 14.73S 30.622 OO 32.30 C 
HETATM 57 C 200 C 372 - 13.594. 14.731 30.756 OO 37.62 C 
HETATM S8 O 200 C 372 - 14.2OO 1544O 31.8.10 OO 41.91 O 
HETATM S9 CB 200 C 372 -11.640 15.817 29.612 OO 30.34 C 
HETATM 60 CG 200 C 372 - 10.185 15.711. 29.13S OO 25.13 C 
HETATM 61 CD1 200 C 372 -9.909 15.210 27.863 OO 20.80 C 
HETATM 62 CD2 200 C 372 -9.161 16.08.2 29.995 OO 22.71 C 
HETATM 63 CE1 200 C 372 -8.592 15.088. 27.45S OO 22.75 C 
HETATM 64 CE2, 200 C 372 -7.842 15.960 29.593 OO 22.47 C 
HETATM 6S CZ 200 C 372 -7.572 15.459 28.324 OO 26.57 C 
HETATM 66 CL 200 C 372 -5.931 15288. 27.829 OO 37.22 CL 
HETATM 67 OXT 200 C 372 - 14.362. 13.982 29.828 OO 4419 O 
END 
TABLE 10 
Atomic coordinates of P14 residues and of the residues involved in the binding of P14 
to the B clamp, in the crystal of P14 peptide co-crystallized with the Bring. 
ATOM 
TER 
ATOM 
TER 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
1 
NH1 
CD2 
CB 
CG2 
OG1 
CD2 
ND1 
CE1 
NE2 
CA 
e 
CB 
CG 
CD1 
CA 
CB 
CG 
CA 
e 
CB 
RG A 
A. 
R 
RG 
RG gt 
RO 
O 
52 
52 
55 
55 
72 
72 
72 
72 
74 
74 
74 
74 
75 
75 
75 
75 
75 
75 
75 
75 
75 
75 
76 
76 
76 
76 
77 
77 
77 
77 
77 
77 
242 
242 
242 
242 
242 
243 
243 
243 
243 
244 
244 
244 
244 
-13.OOO 
-8.771 
-5.062 
-5.795 
-5.728 
-8.679 
-9.451 
-9.367 
-9.848 
-8.715 
-8.481 
-6.976 
-6. SS7 
-9.131 
-10.595 
-11259 
-11.496 
-12.677 
-12.587 
-6.162 
-4709 
-4.078 
-4.648 
-2.885 
-2.204 
-2.431 
-1.853 
-2.845 
-7.701 
-6.353 
-5.277 
-8.234 
-7.827 
-6.480 
-5-451 
-4.812 
-5-193 
-3.865 
-3.152 
-2.245 
-2.366 
14.676 
17.218 
14.269 
15.62O 
13.271 
12.290 
12.319 
11.041 
10.979 
10.024 
8.734 
8.530 
8.002 
7.6O2 
7.832 
7.998 
7.948 
8.158 
8.212 
8.980 
8.899 
10.213 
10.9SO 
10.489 
11.738 
12.671 
14.08O 
15.053 
20.996 
21.18O 
21.2O1 
19.577 
18.915 
21417 
21642 
20.307 
19.613 
19930 
18.662 
18.565 
18.444 
25.384 
22.511 
24.018 
24.122 
24.786 
24.030 
25.270 
26.069 
27.199 
25.494 
26.139 
26.32O 
27.335 
25.325 
25.079 
23.916 
26.130 
25.576 
24.247 
25.337 
25.425 
25.009 
24.212 
25.534 
25.266 
26.488 
26.442 
27.040 
27.178 
27.870 
27.239 
27.285 
26.040 
29.176 
30.163 
3O.SOO 
31.45S 
29.652 
29.719 
30.939 
28.424 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
41.87 N1 
32.76 C 
29.73 C 
26.88 C 
28.48 O 
26.79 N 
28.12 C 
32.47 C 
31.98 O 
30.75 N 
30.80 C 
30.70 C 
29.87 O 
32.OO C 
35.24 C 
37.80 C 
37.36 N 
37.24 C 
38.20 N 
25.93 N 
23.72 C 
27.35 C 
24.69 O 
25.59 N 
25.33 C 
25.95 C 
29.85 C 
31.56 C 
30.57 C 
35.62 C 
31.98 O 
32.60 C 
37.83 C 
34.91 N 
35.21 C 
38.35 C 
37.41 O 
34.76 N 
34.71 C 
39.89 C 
34.64 C 
30 
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TABLE 10-continued 
Atomic coordinates of P14 residues and of the residues involved in the binding of P14 
TER 
ATOM 
ATOM 
ATOM 
ATOM 
TER 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
TER 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
TER 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
TER 
ATOM 
ATOM 
TER 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
to the B clamp, in 
46 
47 
48 
49 
50 
51 
52 
53 
S4 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
8O 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
OO 
O1 
O2 
O3 
O4 
05 
O6 
O7 
O8 
09 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
2O 
21 
22 
CD1 
CE1 
CA 
CB 
CG 
ND2 
CA 
CB 
OG 
CA 
CB 
CG 
SD 
CE 
CA 
CB 
CG 
CD 
CA 
CB 
CG 
SD 
CE 
CA 
CB 
CG 
CD 
NE 
CZ 
TYR 
ARG 
VAL 
VAL 
VAL 
VAL 
GLY 
PH 
PH 
PH 
PH 
PH 
PH 
PH 
PH 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
TY 
TY 
TY 
TY 
TY 
TY 
SER 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
SER 
SER 
SER 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
PRO 
PRO 
PRO 
PRO 
PRO 
PRO 
PRO 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
MET 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
244 
246 
247 
247 
247 
247 
318 
319 
319 
319 
319 
319 
319 
319 
319 
32O 
32O 
32O 
32O 
32O 
32O 
32O 
32O 
323 
323 
323 
323 
323 
323 
343 
344 
344 
344 
344 
344 
344 
346 
346 
346 
360 
360 
360 
360 
361 
361 
362 
362 
362 
362 
362 
362 
362 
362 
363 
363 
363 
363 
363 
363 
363 
364 
364 
364 
364 
364 
364 
364 
364 
365 
365 
365 
365 
365 
365 
365 
365 
365 
-9.362 
-4.800 
-6.175 
-4.260 
-7.101 
-6.439 
-6.062 
-6.4.89 
-6.510 
-4.532 
-3.977 
-4.229 
-3.731 
-6.726 
-6.956 
-5.554 
-4.654 
-7.569 
-7.625 
-8.716 
-3.987 
-5.324 
-6.338 
-7.551 
-7.760 
-8.221 
-9.112 
-8.465 
-9.164 
10.398 
11.101 
-3.897 
-3.189 
-1708 
-2.317 
-O.897 
-2.031 
-4.106 
-3.751 
-5.362 
-6.410 
-6.834 
-7.011 
-7.591 
-8.518 
-7.736 
-9.105 
-6.981 
-7.383 
-8.853 
-9.6OO 
-7.148 
-7.447 
-6.797 
-9.251 
O.606 
1.156 
O.376 
0.559 
O.480 
0.177 
1844 
2.490 
3.039 
3.003 
3.457 
4.441 
4.900 
6.194 
5.967 
6.403 
18.335 
14.658 
15.272 
15.077 
-0.481 
-2005 
-1039 
-1.419 
-2.591 
-O.862 
O.004 
1368 
2.174 
-0.410 
-0.616 
-O.926 
-0.066 
O.636 
0.595 
1.031 
3.146 
3.669 
3.953 
4.485 
4.733 
1.305 
3.668 
S.O23 
5.988 
3.839 
2.498 
8.687 
9.493 
8.441 
8.921 
10.498 
10.304 
6.199 
4.254 
6.5O1 
6.303 
4.822 
4.331 
7.238 
7.477 
8.227 
8.087 
4.091 
2.677 
2.456 
3.409 
2.2O3 
3.380 
4SOS 
1179 
O.744 
O.O10 
-0.6O2 
-0.264 
0.379 
-O.88O 
-1.575 
O.042 
-0.701 
-2.213 
-2.647 
-0.209 
-O.881 
-0.321 
O.754 
1998 
34.959 
32.377 
32.614 
31.013 
31.341 
29.819 
28.794 
27.399 
27.065 
28.741 
29.823 
29.839 
30.867 
26.564 
25.155 
24.63S 
24.695 
24.508 
23.004 
22.426 
23.786 
23.316 
24.224 
23.803 
22.459 
36.401 
37.518 
37.143 
36.815 
38.375 
38.569 
33.543 
34.475 
28.606 
27.649 
29.926 
30.938 
29.791 
27.465 
29.534 
30.527 
3O434 
29.325 
30.220 
31.376 
32.828 
34.OOS 
31.569 
31.502 
31.064 
3O.801 
32.941 
33.754 
32.971 
30.970 
30.632 
31.848 
32.572 
29.473 
28.110 
26.856 
26.686 
32.084 
33.225 
32.924 
31.869 
33.655 
34.954 
35.483 
36.451 
36.291 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
he crystal of P14 peptide co-crystallized with the Bring. 
56.46 N1 
45.61 C 
44.77 C 
45.81 C 
28.54 O 
25.76 N 
2529 C 
26.9S C 
25.62 O 
26.12 C 
26.52 C 
30.64 C 
31.78 C 
23.99 N 
24.11 C 
27.35 C 
24.6S O 
23.58 C 
34.43 C 
24.70 N 
24.01 C 
27.27 C 
27.85 C 
28.48 C 
39.89 C 
35.47 O 
31.45 C 
35.04 C 
35.77 O 
35.78 C 
35.22 C 
33.22 C 
39.59 O 
31.20 C 
30.76 O 
31.93 C 
32.54 C 
28.46 C 
28.23 C 
27.43 N 
28.06 C 
30.78 C 
29.96 O 
30.87 C 
34.33 C 
37.58s 
34.59 C 
26.83 N 
25.64 C 
31.65 C 
29.62 O 
26.32 C 
30.73 C 
26.98 C 
28S9 N 
28.63 C 
33.94 C 
30.49 O 
30.86 C 
34.27 C 
37.20 S 
34.67 C 
36.79 N 
38.26 C 
41.53 C 
41.37 O 
40.76 C 
49.70 C 
57.33 C 
62.68 N 
83.24 C 
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TABLE 10-continued 
Atomic coordinates of P14 residues and of the residues involved in the binding of P14 
to the B clamp, in the crystal of P14 peptide co-crystallized with the Bring. 
ATOM 23 NH1 ARG. A 365 - 17.085 2.33S 35.2O2 OO 79.01 N1 
ATOM 24 NH2 ARG. A 365 - 16.159 2.91.6 37.217 OO 72.47 N 
TE 25 ARG A 365 
HETATM 26 O HOH A 393 - 12.258 0.479 23.904 OO 3O49 O 
HETATM 27 O HOH A 434 -11.324 4.559 22.768 OO 39.46 O 
HETATM 28 O HOH A 453 - 10.378 2.373 23.903 OO 29.67 O 
HETATM 29 O HOH A 463 -8.977 20.736. 30.414 OO 61.87 O 
HETATM 30 O HOH A 490 -11.833 19.233 26.362 OO 59.30 O 
HETATM 31 O HOH A 494 -9.709 19.924, 32.759 OO 46.54 O 
HETATM 32 O HOH A 516 - 16.291 -3.291 31.343 OO SO.13 O 
HETATM 33 O HOH C 45 - 6.988 2.274 27.402 OO 24.52 O 
HETATM 34 O HOH C 219 - 14.432 8.577 32.316 OO 42.19 O 
HETATM 35 O HOH C 236 -12.880 18.057 33.132 OO 45.93 O 
HETATM 36 C ACE C 367 - 14.148 1368. 29.378 OO 3O4S C 
HETATM 37 O ACE C 367 - 13.83S 1.713 3 O.SO2 OO 36.32 O 
HETATM 38 CH3 ACE C 367 - 15.035 0.134 29.141 OO 23.39 C 
ATOM 39 N GLN C 368 - 13.746, 1957 28.290 OO 33.32 N 
ATOM 40 CA GLN C 368 - 12.873 3.100 28.115 OO 32.69 C 
ATOM 41 C GLN C 368 - 13.283 4.349 28.853 OO 33.34 C 
ATOM 42 O GLN C 368 - 14.33O 4.821 28.622 OO 32.62 O 
ATOM 43 CB GLN C 368 - 12.617 3.443 26.659 OO 30.16 C 
ATOM 44 CG GLN C 368 - 11.47O 45O2 26.458 OO 2948 C 
ATOM 45 CD GLN C 368 - 10.087 4.218. 27.096 OO 29.80 C 
ATOM 46 NE2 GLN C 368 -9.514 3.231, 26.666 OO 25.11 N 
ATOM 47 OE1 GLN C 368 -9.495 4.916 28.005 OO 31.46 O 
TE 48 GLN C 368 
HETATM 49 N ALC C 369 - 12.348 4.783 29.710 OO 32.73 N 
HETATM SO CA. ALC C 369 -12.5OO 6.004 30.548 OO 34.14 C 
HETATM 51 C ALC C 369 -11.878 7.192 29.752 OO 36.64 C 
HETATM 52 O ALC C 369 -10.984 7.069 28.869 OO 32.46 O 
HETATM S3 CB ALC C 369 -11.739 S.83O 31.889 OO 34.SS C 
HETATM S4 CG ALC C 369 - 12.26S 4.559 32.6SO OO 35.64 C 
HETATM SS CD1 ALC C 369 -13.8O8 4.654 32.962 OO 39.49 C 
HETATM S6 CD2 ALC C 369 -11.323 4.206 33.835 OO 33.24 C 
HETATM 57 CE1 ALC C 369 -14.214 3.964 34.3O2 OO 41.77 C 
HETATM S8 CE2 ALC C 369 -11.911 3.02O 34.514 OO 36.86 C 
HETATM S9 CZ. ALC C 369 - 13.067 3.588 35.295 OO 40.10 C 
ATOM 60 N ASP C 370 - 12.406 8.334 30.145 OO 40.84 N 
ATOM 61 CA. ASP C 370 - 12.054 9.67O 29.629 OO 43.94 C 
ATOM 62 C ASP C 370 -10.90S 10.238 30.494 OO 41.92 C 
ATOM 63 O ASP C 370 -10.900 10.094 31.7O6 OO 39.99 O 
ATOM 64 CB ASP C 370 - 13.194 10.609 29.791 OO 48.03 C 
ATOM 6S CG ASP C 370 - 14.398 10.233 29.003 OO 55.27 C 
ATOM 66 OD1 ASP C 370 - 14.373 9.336 28.084 OO S6.63 O 
ATOM 67 OD2 ASP C 370 -15.398 10.873 29.360 OO 59.41 O1 
ATOM 68 N LEU C 371 -9.929 10.917 29.882 OO 43.04 N 
ATOM 69 CA LEU C 371 -8.785 11.787 30.606 OO 42.42 C 
ATOM 70 C LEU C 371 -9.335 12.911. 31.330 OO 47.23 C 
ATOM 71 O LEU C 371 -8.808 13.271 32.377 OO 47.SS O 
ATOM 72 CB LEU C 371 -7.621 12.26S 29.726 OO 37.30 C 
ATOM 73 CO LEU C 371 -6.599 11.206. 29.251 OO 32.23 C 
ATOM 74 CD1 LEU C 371 -5.841 11.622 27.996 OO 27.72 C 
ATOM 75 CD2 LEU C 371 -5.712 10.688 30.370 OO 32.57 C 
TER 76 LEU C 371 
HETATM 77 N. ZCL C 372 - 10.331 13.589 30.796 OO 51.48 N 
HETATM 78 CA ZCL C 372 - 11.007 14.833 31.271 OO S6.21 C 
HETATM 79 C ZCL C 372 - 12.356 14.343 31.982 OO 59.74 C 
HETATM 80 O ZCL C 372 - 13.391. 14.104 31.274 OO 58.69 O 
HETATM 81 CB ZCL C 372 - 11.091 16.08S 30.288 OO SS-89 C 
HETATM 82 CG ZCL C 372 -9.672 16.291 29.799 OO 57.05 C 
HETATM 83 CD1 ZCL C 372 -9.347 15.682 28.574 OO S7.40 C 
HETATM 84 CD2 ZCL C 372 -8.663. 17.02O 30.494 OO S744 C 
HETATM 85 CE1 ZCL C 372 -8.088 15.8O3 28.089 OO 59.91 C 
HETATM 86 CE2 ZCL C 372 -7.347 17.172. 29.984 OO S7.91 C 
HETATM 87 CZ ZCL C 372 - 7.057 16.515 28.746 OO S7.04 C 
HETATM 88 CLE1 ZCL C 372 -7.803 15.O4S 26.63S OO 66.69 CL 
HETATM 89 CLZ ZCL C 372 -S.SO7 16.525 27.966 OO SO.27 CL 
HETATM 90 OXT ZCL C 372 - 12.339 14.16O 33.254 OO 61.54 O 
END 
1.2.5. Thermodynamic Analysis of the Pseudo Peptides K. Values determined in these experimental conditions were 
Interaction with the Ring. slightly different from those obtained by SPR, the same ten 
ITC experiments were conducted on selected peptides in 65 dency was observed for all peptides (Table 11). The largest 
order to determine the thermodynamics parameters of their differences are observed for low affinity peptides (P1, P3, P6) 
interaction with the ring (Table 11 and FIG. 8). Although the while, for higher affinity peptides (P7, P11, P12, P13 and 
35 
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P14), both techniques yielded similar values. The introduc 
tion of modifications, Cha group in position 2 and p-methyl, 
p-chloro and p-bromo groups on Fs, increases the affinity of 
the ligand, reaching respectively about 380, 100, 65 and 150 5 
nM range, as compared to the 1-2 uMaffinity of the reference 
natural peptide P1 (Table 11). A strong correlation is observed 
Beta Pep 
(uM) 
3 O 
3 O 
3 O 
3 O 
(uM) 
4 OO 
4 OO 
4 OO 
4 OO 
4 OO 
4 OO 
4 OO 
4 OO 
36 
between AH and AS values (FIG. 8), which reflects an 
enthalpy–entropy compensatory effect, already observed in 
other systems' . This correlation accounts for the small 
AG variation among the various peptides (FIG. 8). As 
reported earlier', this correlation suggests that the observed 
desolvation of the pocket upon ligand interaction plays a 
major role in the binding process. 
TABL E 11 
ITC experiments on selected f binding peptides. 
Name 
P1 (SEQ ID 
No: 1) 
RQLVLGL 
P3 (SEQ ID 
No : 3) 
RQLWLF 
P6 (SEQ ID 
No : 6) 
AcQLDLF 
P7 (SEO ID 
No. 7) 
AcQChaDLF 
P11 (SEQ ID 
No: 11) 
AcOChaDLpMeF 
P12 (SEQ ID 
No: 12) 
AcOChaDLpClF 
P13 (SEQ ID 
No: 13 
AcOChaDLpBrF 
P14 (SEQ ID 
No: 14) 
AcQChaDLudiClF O 
Ko ICso AH AS (cal/ AG 
N (nM) SPR (nM) (cal/Mol) mol/deg) (Kcal/mol) 
33 1579 885O - 4 O87 12.8 -79 
31 2012 -55 OO 7.6 -77 
54 2816 862O -5769 6. OS -7.5 
45 232O -5699 6. 6 -76 
... 11 82O 112O -1. 13 10' -1. O. 4 -81. 
... 14 613 -1. 11 10' -9. O8 -83 
74 246 17O -2. 13 10' - 41.2 -8.9 
76 222 –2. O5 1 o' -385 -8.9 
95 4 O1 26 O -1. 48 10' -2O. 4 -8. 6 
95 362 -1. 44 10' -19. O -8. 6 
O2 89 16 O -1.5 O? -1.8.1 -9. 6 
... O 6 122 -1. 43 10' -16.3 -94 
85 136 96 -1.81 10' -29.3 -93 
83. 167 -1.52 10' -2O.2 -91 
91 73 77 -1.89 10' -3 O. 8 -9. 6 
9 O 55 -1.81 10' -27. 6 -9.8 
A. AH-TAS. 
All experiments were performed at 25° C. Results from SPR experiments (IC50) are 
added for Comparison purposes. 
number of binding sites per B monomer. 
US 9,133,240 B2 
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The effect of the various modifications introduced in the 
peptides can be estimated from the AAG values (see Table 
12). The Chamoiety in position 2 contributes to the increased 
interaction by -0.66 kcal/mol as compared to the natural 
pentapeptide P6. While the introduction of a methyl substi 
tution on the ring of the terminal phenylalanine residue is 
detrimental to the affinity (+0.25 kcal/mol), halogen modifi 
cation results in a graduate effect on ligand affinity 
(p-bromo-p-chloro-3,4-dichloro). The chloro modification 
in para position contributes for the main part to the increased 
affinity (-0.6 kcal/mol). This contribution can result partly 
from an increased hydrophobic character of the halogen 
modified F residue, as well as from dehydration of both 
peptide and sub site 1° and reorganization of water mol 
ecules as observed by comparing free and bound B interacting 
pockets (FIG.1AB). In comparison, the second chlorine atom 
(metaposition) in P14 only contributes for -0.2 kcal/mol and 
the para-bromo modification contribution to the binding 
energy is two times lower (-0.28 kcal/mol) than the corre 
sponding para-chloro modification. 
TABLE 12 
10 
15 
38 
Residue Rs is also shifted by an angle of 46° toward 
residue Lee, triggering the opening of a platform shaped by 
Rsss, Pses, Mac and Vaa, where the La residue of the peptide 
locates (FIG. 1BC). The global dynamic of this structural 
modification has been modeled, showing that, as the ligand 
binds into the pocket, a groove forms that joins Subsite 1 and 
Subsite 2, in which the extended peptide can adapt. 
The correlation between side chains orientations and the 
presence of a peptide in the binding pocket Suggests that these 
two side chains might play a strategic function in the ligand 
binding process. The pocket could adopt two configurations: 
a closed configuration where the Me side chains lies in the 
path between the two subsites of the pocket, thus impeding 
the formation of an efficient binding site (FIG. 1A). Alterna 
tively, an open configuration where the Me side chains 
shifts by about 180°, allowing ligand binding into the groove 
that joins the two subsites, as well as the opening of the 
platform so that the peptide establishes optimal interactions. 
At present, it is not known if the fully efficient binding pocket 
is readily available at the surface of the protein, or is struc 
effects of modifications introduced in the various pentapeptides 
measured from the AAG values extracted from ITC experiments data. The 
P6 sequence (AcQLDLF) is chosen as a reference. AAG = AGi - AGi. 
AGli AG 
P6, P7 P7, P7, P7 P11. P11. P11, P12, P13, P13, 
P7 P11 P12 P14 P13 P12 P14 P13 P14 P12 P14 
Compared Lif F. F. F. F: pMeF pMeF/diCIF pMeF pCIF pBrF7 pBrF/ 
residues Cha pMeF pCIF diCIF pBrF pCIF pBrF diCIF pCIF diCIF 
AAG -0.66 +0.25 -0.6 -0.8 -0.28 -0.85 -1.05 -0.53 -0.2 -0.32 -0.52 
(Kcal/mol) 
35 
1.3. Discussion. 
1.3.1. The Fully Efficient B Binding Pocket is Formed 
Upon Ligand Binding. 
Many cellular factors involved in replication and genome 
integrity Survey processes require a peptide mediated inter 
action with the replisome sliding clamp in order to fulfill their 
function. This interaction has been structurally fully charac 
terized in prokaryotes' ' ' and eucaryotes. In our pre 
viously published structure (1OK7), the fring interacts with 
only one peptide, leaving one binding pocket free'. This 
gives the opportunity to compare the structure of a peptide 
free versus a peptide-bound pocket and to get insights into the 
dynamic of the pocket upon peptide binding. Although the 
general structures of the free or bound pockets are similar, as 
estimated by the Co. chain conformation (rmsd=0.36A), the 
side chains of several residues undergo major movements 
(FIG. 6), notably residues Me and Sa side chains which 
are displaced in a concerted way, and residue Rs. The con 
certed shift of Me and Sa side chains probably is a struc 
tural marker for the presence of a peptide ligand in the binding 
pocket. In absence of the ligand, these residues adopt a so 
called close conformation where the Me side chain is ori 
ented toward residue His and separates Subsite 1 and Subsite 
2 (PDB IDs 2POL, 1MMI and 1 OK7 (monomer A)) (FIG. 6). 
Alternatively, in all fring bound structures (1UNN, 1 OK7 
(monomer B), 3D1E, 3D1F), the residues are shifted by 180° 
in an open conformation, allowing the opening of a cleft 
joining the two subsites (FIG. 1BC). One exception is found 
in the structure of B co-crystallized with the Pol II peptide 
(3D1E) where no ligand is observed in monomer B, although 
the two residues adopt an open conformation'. This may 
result from a partial occupancy of the pocket, making difficult 
the detection of the peptide. 
40 
45 
50 
55 
60 
65 
tured by the binding of a specific ligand, according to a bona 
fide induced fit model. Previous observations for a ligand 
binding site on the cytokine IL-27 reveal that a portion of the 
binding site is adaptive and can form a hydrophobic channel 
upon ligand binding. A similar adaptive process could occur 
for the B binding pocket and would ensure the binding speci 
ficity of ligand proteins. Although the details of the dynamic 
process of this binding site formation are not known yet, this 
observation is likely to have major implications for the design 
of high affinity ligands. 
1.3.2. Structure-Based Design of High Affinity Ligands. 
The inventors have studied the interaction of various pep 
tides with the E. coli processivity ring. Starting from the 
natural sequence of the Pol IV DNA polymerase interacting 
peptide (P1, ROLVLGL, SEQID No: 1), they have sequen 
tially modified the peptide in order to increase its interaction 
strength and concomitantly to limit its size. The affinities 
were measured by biochemical assays, SPR and ITC, and 
despite a difference in sensitivity of these various techniques, 
the relative affinities of the peptides were similar. From the 
P1-?3 complex (PDB 1OK7), a minimal acetylated peptide 
(P6, AcOLDLF) was first delineated and found to bind about 
eight times tighter than P1. Then, the crystallographic struc 
ture of the P1-B and P6-3 complexes were used together with 
modelling informations to guide modifications at specific 
positions (corresponding to residues L and Fs of P6, 
AcOLDLF), resulting in a dramatic increase of the modified 
peptides affinity for the Bring interacting pocket. This gain 
essentially results from an increase in hydrophobic interac 
tions. A first improvement was achieved by the introduction 
of a cyclohexylalanyl residue at the P6-L2 position. Although 
US 9,133,240 B2 
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position 2 does not correspond to a major binding pocket on 
the B-clamp, the simple modification to a cyclohexylalanyl 
residue(P7) improved the affinity by a factor 6 with respect to 
the P6 peptide (Table 1), indicating that shallow secondary 
sites can still prove useful in a global optimization scheme. 
The other interesting gain was achieved by the addition of 
halogen atoms on the benzyl ring of the F residue. Interest 
ingly, the chlorine atom when introduced at the metaposition, 
forms a halogen bond that further strengthens the interaction. 
P14, which combines both the Cha and a 3,4-dichlorophe 
nylalanine residue, displays the highest affinity, around 60 
(+10) nM as measured by ITC, which represents a 10 to 15 
fold increase in binding as compared to P6 and a 4 fold 
increased as compared to the whole PolIV DNA polymerase. 
The double Fring substitution contributes for -0.8 kcal/mol 
to the overall interaction. The para-chloro substitution pro 
vides most of the contribution to the binding while the meta 
chloro, involved in a halogen bond, only contributes for one 
fourth of the total free energy. 
Interestingly, halogen Substituted aromatic ligands were 
also recently independently identified for the B-clamp using a 
chemical library screening strategy. A compound, named 
RU67, was identified as a Bligand inhibiting the E. colipol III 
enzyme with a Ki of 10 uM". It contains a di-bromo substi 
tuted aromatic ring which is deeply inserted in Sub site 1 and 
almost superimposes with the peptide La residue of the Pol IV 
binding peptide. One bromine atom does not form any inter 
action while the other forms a halogen bond with B residue 
T (d=3.02 A and 0-133.21). This latter interaction is 
similar to that observed for the chlorine atom in metaposition 
of F in P14. 
This specific positioning of halogen substituted ligands in 
subsite 1 of the B-clamp contrasts with the wider range of 
positions occupied by natural amino acids in the same pocket. 
Indeed, the comparison of different structures of B in complex 
with various natural peptides (1OK7, 3D1E, 3D1F)7 
reveals that, while most of the peptide residues adopt the same 
overall conformation within the pocket, the position of the 
last C-terminal residues of the interacting sequence varies in 
Subsite 1. This suggests that no specific interaction is estab 
lished with specific B residue, but instead that this hydropho 
bic interaction, delocalized in all subsite 1, contributes 
mainly to paste the peptide onto the B Surface. 
In conclusion, the structure-based approach described 
herein allows the design of ligands that bind two orders of 
magnitude tighter than the natural peptide P1, reaching the 
10 M range, and 4 fold more than the Pol IV enzyme. This 
increase in affinity relies both on chemical substitutions intro 
duced on the peptide that increase the hydrophobic interac 
tions and on the fact that the bidentate interaction of the ligand 
in the binding pocket is retained. This interaction mode pro 
motes the modeling of an efficient binding site, possibly 
through an induced-fit process. 
Further designs of high affinity ligands should also take 
into account the dynamic nature of the binding site formation. 
These observations are likely to have major implications for 
the development of new antibiotic compounds. 
Example 2 
Synthesis and Functional Characterization of Further 
Peptides Derived from P7 (SEQID No. 7), P12 
(SEQID No. 12), P14 (SEQID No. 14), P23-P30 
(SEQID Nos: 23-30) 
Compounds P23 to P28 (SEQ ID No: 23 to SEQ ID No: 
28), which are analogues of P7 and P14, have been prepared 
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40 
to (i) remove carboxylic side functions and monitor the influ 
ence of R and guanidino groups and conformational con 
straint. Compounds P23 to P28 have been prepared as previ 
ously reported in example 1 starting from Fmoc-Phe Wang 
resin or from o-chlorotrityl chloride resin. The linear precur 
sor of P29 (Ac-RQChaKLF-OH, P27, SEQ ID No. 27) is 
prepared as described in example 1. In the case of compound 
P30 (SEQID No. 30), the linear precursor P28 (SEQID No: 
28) requires the use of a beta amino acid (Fmoc-beta-HPhe 
OH) which is commercially available from Sigma-Aldrich. In 
the case of P29 and P30, lactam formation between the amino 
group of the lysine side chain and the C-terminal carboxylic 
function was performed using standard methods as described 
in the literature (Robert C. Reid, Giovanni Abbenante, 
Stephen M. Taylor, and David P. Fairlie; J. Org. Chem., 2003, 
68 (11), pp. 4464-4471). The cyclization which requires the 
activation and coupling of a peptidyl-Arg residue (P27 or 
P28) was carried out in DMF at room temperature using BOP 
as a coupling agent and diisopropylethylamine as the base and 
monitored by analytical 
RP-HPLC. Briefly, a solution of the fully deprotected pep 
tide 27 or 28 (1 equivalent) in DMF (10-1M) and diisopro 
pylethylamine (5.5 equivalent) was stirred at room tempera 
ture (about 20° C.) until homogeneous. Benzotriazole-1-yl 
oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate or BOP reagent (1.08 equivalent) was 
added, and the solution was stirred at room temperature 
(about 20°C.) for 2 h. A saturated Bicarbonate solution was 
added and the solid product was filtered off, washed on the 
filter with ether, and dried under high vacuum. The crude 
product was dissolved in 50% CHCN/50% water (1 L) and 
purified by C18 RP-HPLC. The peak containing the cyclic 
peptide was collected and lyophilized. 
Example 3 
New Peptides Derived from P14, SPR Experiments 
Based on the crystals analysis, the inventors have used 
peptide P14 (Bu29) as a scaffold to derive new variants with 
the aim of deciphering new properties to the ligand Such as 
increased affinity, increased solubility, or increased cell pen 
etration. 
TABL E 13 
sequences of the P14 derivative peptides. 
Peptide 
ale Sequence MW SEQ ID No: 
P14 Ac Q Cha D L diClF 14 
P14 - 4 Ac R O Cha N. L. diClF 94 O 36 
P14 - 5 Cin R O Cha N. L. diClF 1028 37 
P14 - 6 Ac R O Cha R L diClF 98 OS 38 
P14-7 Ac R O Cha R L. F 913 39 
P1 4-8 Ac R O Cha K. L. F 886 4 O 
AC: 
Cin: 
acetyl group; 
Cinnamoyl group. 
The rationale directing the design of these peptides was 1) 
to extend the interaction of the N-terminal part of the peptide 
with the edge of the binding pocket, 2) to take advantage of 
the position of the D residue of peptide P14, that points 
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towards the solvent, to introduce positively charged residues 
that will increase the solubility and the membrane penetrating 
capabilities of the peptide. 
The affinity of these peptides for the binding pocket was 
measured by SPR, by defining the concentration of ligand that 5 
challenges 50% of the binding of the natural peptide P1 
(RQLVLGL), thus defining a Ki. Results are given in table 14 
TABL E 14 
10 
relative affinity of P14 derivative pep 
tides for the beta ring binding pocket, 
as measured by SPR experiments. 
Ki 
(nM) 
Peptide 
ale 
SEO ID 
Sequence No : 15 
p7 Ac Q Cha D. L. F 17O 7 
P14 Ac Q Cha D L diClF 85 14 
P14 - 4 Ac R O Cha N. L. diClF insoluble 36 
P14 - 5 Cin R O Cha N. L. diClF 3.250 37 
P14 - 6 Ac R O Cha R L diClF 10 OOO 38 
P14-7 Ac R O Cha R L. F 10 OOO 39 
25 
P14 - 8 Ac R O Cha K. L. F 904 4 O 
CONCLUSIONS 
30 
None of the peptides is a better binder than P14. One of 
them, P1 4-8, still bind the target with a 1 uMaffinity. 
As compared to P14 (SEQID No: 14), the introduction of 
R and K residues in the sequence (P14-8, SEQ ID No: 40) 
results in a 10 fold decrease in affinity. 
The diClF to F substitution results in a 2 fold decrease in 
affinity (compare P14 and P7). Thus the Rand K subtitutions 
in peptide P14-8 may contribute to a 5 fold decrease (1000/ 
200) of the affinity as compared to P14. 
P14-7 and P14-8 differ from each other by the 5' residue 
(R for #7 and K for #8). Comparison of the relative affinity of 
these two peptides suggests that Kresidue is a better choice to 
maintain affinity. Moreover, comparing P7 and P14-7, which 
differ by R1 and R5 residues, indicates an affinity ratio of at 
least 50 (#10 000/200). 
Altogether, this suggests that the K5 residue in P14-8 may 
contribute to decrease the affinity by a factor of 10 (P14-7/ 
P7=5 and P14-8/P7–50). 
35 
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212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 1 
Arg Glin Lieu Val Lieu. Gly Lieu 
1. 5 
<210s, SEQ ID NO 2 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 2 
Arg Glin Lieu Val Lieu. Lieu. 
1. 5 
<210s, SEQ ID NO 3 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 3 
Arg Glin Lieu Val Lieu. Phe 
1. 5 
<210s, SEQ ID NO 4 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 4 
Arg Glin Lieu Val Phe Lieu. 
1. 5 
<210s, SEQ ID NO 5 
&211s LENGTH: 5 
212. TYPE: PRT 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 5 
Glin Lieu. Asp Lieu. Phe 
1. 5 
<210s, SEQ ID NO 6 
&211s LENGTH: 5 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
<4 OOs, SEQUENCE: 6 
Glin Lieu. Asp Lieu. Phe 
1. 5 
US 9,133,240 B2 
- Continued 
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47 
SEO ID NO 7 
US 9,133,240 B2 
- Continued 
LENGTH: 5 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic peptide 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (2) ... (2) 
OTHER INFORMATION: Xaa = Cha (beta-cyclohexyl-L-alanyl 
<4 OO > SEQUENCE: 7 
Glin Xaa Asp Lieu. Phe 
1. 5 
SEQ ID NO 8 
LENGTH: 5 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic peptide 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (2) ... (2) 
OTHER INFORMATION: Xaa = hCha (homocyclohexylalanine) 
<4 OOs, SEQUENCE: 8 
Glin Xaa Asp Lieu. Phe 
1. 5 
SEO ID NO 9 
LENGTH: 5 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic peptide 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (2) ... (2) 
OTHER INFORMATION: Xaa = hlieu (homoleucine) 
<4 OOs, SEQUENCE: 9 
Glin Xaa Asp Lieu. Phe 
1. 5 
SEQ ID NO 10 
LENGTH: 5 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (2) ... (2) 
OTHER INFORMATION: Xaa 
FEATU RE: 
NptCly 
INFORMATION: Synthetic peptide 
(neopentylglycul 
48 
49 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (2) ... (2) 
223 OTHER INFORMATION: Xaa 
<4 OOs, SEQUENCE: 10 
Glin Xaa Asp Lieu. Phe 
1. 
US 9,133,240 B2 
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NptGly (neopentylglycyl) 
Cha 
INFORMATION: Non-natural peptide 
(cyclohexylalanine) 
INFORMATION: METHYLATION Xaa = p-MeF (p-methylphenylalanine) 
5 
SEQ ID NO 11 
LENGTH: 5 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (2) ... (2) 
OTHER INFORMATION: Xaa 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (5) . . (5) 
OTHER 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (5) . . (5) 
<4 OOs, SEQUENCE: 11 
Glin Xaa Asp Lieu. Xaa 
1. 
Cha 
INFORMATION: Non-natural peptide 
(cyclohexylalanine) 
5 
SEQ ID NO 12 
LENGTH: 5 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (2) ... (2) 
OTHER INFORMATION: Xaa 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (5) . . (5) 
OTHER INFORMATION: Xaa 
<4 OOs, SEQUENCE: 12 
Glin Xaa Asp Lieu. Xaa 
1. 
pClF (p-chloro-phenylalanine) 
INFORMATION: Non-natural peptide 
5 
SEQ ID NO 13 
LENGTH: 5 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (2) ... (2) 
OTHER INFORMATION: Xaa 
FEATU 
NAME/ 
RE: 
KEY: MISC FEATURE 
Cha (cyclohexylalanine) 
&222s. LOCATION: 
<223> OTHER INFORMATION: Xaa = pBrF (p-bromo-phenylalanine) 
<4 OOs, SEQUENCE: 
US 9,133,240 B2 
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- Continued 
(5) . . (5) 
13 
Glin Xaa Asp Lieu. Xaa 
1. 
SEQ I 
LENGT 
TYPE : 
FEATU 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER INFORMATION: Xaa 
D NO 
H: 5 
PRT 
RE: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
<4 OOs, SEQUENCE: 
5 
14 
ORGANISM: Artificial Sequence 
RMATION: Non-natural peptide 
MOD RES 
(1) . . (1) 
RMATION: ACETYLATION 
MISC FEATURE 
(2) ... (2) 
RMATION: Xaa Cha (cyclohexylalanine) 
MISC FEATURE 
(5) . . (5) 
diClF (3, 4-dichloro-phenylalanine) 
14 
Glin Xaa Asp Lieu. Xaa 
1. 5 
SEO ID NO 15 
LENGTH: 6 
TYPE; PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Non-natural peptide 
FEATURE: 
NAME/KEY: MOD RES 
LOCAT ION: (1) . . (1) 
OTHER INFORMATION: ACETYLATION 
<4 OOs, SEQUENCE: 15 
Arg Glin Lieu Val Lieu. Phe 
1. 
SEQ I 
LENGT 
TYPE : 
FEATU 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
D NO 
H: 5 
PRT 
RE: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
<4 OOs, SEQUENCE: 
Glin Xaa Asp Xaa 
1. 
5 
16 
ORGANISM: Artificial Sequence 
RMATION: Non-natural peptide 
MOD RES 
(1) . . (1) 
RMATION: ACETYLATION 
MISC FEATURE 
(2) ... (2) 
RMATION: Xaa Cha (cyclohexylalanine) 
MISC FEATURE 
(4) . . (4) 
RMATION: Xaa hLeu (homoleucine) 
16 
Phe 
5 
<210s, SEQ ID NO 17 
&211s LENGTH: 5 
TYPE : PRT 
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- Continued 
ORGANISM: Artificial Sequence 
FEATURE: 
INFORMATION: Non-natural sequence 
FEATURE: 
NAME/KEY: MOD RES 
OTHER 
LOCAT 
OTHER 
LOCAT 
OTHER 
ION: (1) . . (1) 
INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
ION: 
INFORMATION: Xaa 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCAT 
OTHER 
ION: 
INFORMATION: Xaa 
<4 OOs, SEQUENCE: 
Glin Xaa Asp Xaa 
1. 
SEQ I 
LENGT 
TYPE : 
FEATU 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
D NO 
H: 5 
PRT 
RE: 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE; 
KEY: 
ION: 
INFO 
<4 OOs, SEQUENCE: 
Glin Xaa Asp Xaa 
1. 
SEQ I 
LENGT 
TYPE : 
FEATU 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
D NO 
H: 5 
PRT 
RE: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
<4 OOs, SEQUENCE: 
Glin Xaa Asp Xaa 
1. 
(2) ... (2) 
Cha (cyclohexylalanine) 
(4) . . (4) 
Cha (cyclohexylalanine) 
17 
Phe 
5 
18 
ORGANISM: Artificial Sequence 
INFORMATION: Non-natural peptide 
MOD RES 
(1) . . (1) 
RMATION: ACETYLATION 
MISC FEATURE 
(2) ... (2) 
RMATION: Xaa Cha (cyclohexylalanine) 
MISC FEATURE 
(4) . . (4) 
RMATION: Xaa hCha (homocyclohexylalanine) 
18 
Phe 
5 
19 
ORGANISM: Artificial Sequence 
RMATION: Non-natural sequence 
MOD RES 
(1) . . (1) 
RMATION: ACETYLATION 
MISC FEATURE 
(2) ... (2) 
RMATION: Xaa Cha (cyclohexylalanine) 
MISC FEATURE 
(4) . . (4) 
RMATION: Xaa NptGly (neopentylglycyl) 
19 
Phe 
5 
SEQ ID NO 2 O 
LENGTH: 5 
TYPE : PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Non-natural peptide 
FEATURE: 
54 
US 9,133,240 B2 
55 
- Continued 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (2) ... (2) 
223 OTHER INFORMATION: Xaa 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (5) . . (5) 
223 OTHER INFORMATION: Xaa 
Cha (cyclohexylalanine) 
Cha (cyclohexylalanine) 
<4 OOs, SEQUENCE: 2O 
Glin Xaa Asp Lieu. Xaa 
1. 5 
<210s, SEQ ID NO 21 
&211s LENGTH: 5 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural peptide 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (2) ... (2) 
<223> OTHER INFORMATION: Xaa = Cha (cyclohexylalanine) 
<4 OOs, SEQUENCE: 21 
Glin Xaa Asp Lieu. Trp 
1. 5 
<210s, SEQ ID NO 22 
&211s LENGTH: 5 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural peptide 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (2) ... (2) 
223 OTHER INFORMATION: Xaa 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (5) . . (5) 
223 OTHER INFORMATION: Xaa 
Cha (cyclohexylalanine) 
Atda (2-amino-tetradecanoic acid) 
<4 OOs, SEQUENCE: 22 
Glin Xaa Asp Lieu. Xaa 
1. 5 
<210s, SEQ ID NO 23 
&211s LENGTH: 5 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (2) ... (2) 
<223> OTHER INFORMATION: Xaa = Cha (cyclohexylalanine) 
22 Os. FEATURE: 
56 
57 
<221s NAME/KEY: MISC FEATURE 
&222s. LOCATION: 
223 OTHER INFORMATION: Xaa = 
<4 OOs, SEQUENCE: 
Glin Xaa Asn Lieu. Xaa 
1. 
SEQ I 
LENGT 
TYPE : 
FEATU 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
D NO 
H: 6 
PRT 
RE: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
<4 OOs, SEQUENCE: 
Arg Glin Xaa Asn 
1. 
SEQ I 
LENGT 
TYPE : 
FEATU 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
D NO 
H: 6 
PRT 
RE: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
RE: 
KEY: 
ION: 
INFO 
<4 OOs, SEQUENCE: 
Arg Glin Xaa Arg 
1. 
SEQ I 
LENGT 
TYPE : 
FEATU 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
OTHER 
FEATU 
NAME/ 
LOCAT 
D NO 
H: 5 
PRT 
RE: 
RE: 
ION: 
RE: 
ION: 
RE: 
ION: 
(5) . . 
23 
5 
24 
24 
5 
25 
25 
5 
26 
(5) 
MOD RES 
(1) . . 
RMATION: 
(1) 
(3) 
(6) 
Cell Xala 
MOD RES 
(1) . . 
RMATION: ACETYLATION 
(1) 
(3) 
(6) 
Cell Xala 
KEY: MOD RES 
(1) . . 
INFORMATION: ACETYLATION 
(1) 
(2) 
(5) 
US 9,133,240 B2 
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di - chloro-phenylalanine carboxamide 
ORGANISM: Artificial Sequence 
RMATION: Non-natural peptide 
addition of a cinnamoy group 
MISC FEATURE 
(3) . . 
RMATION: Xaa 
MISC FEATURE 
(6) . . 
RMATION: Xaa 
MISC FEATURE 
(3) . . 
RMATION: Xaa 
MISC FEATURE 
(6) . . 
RMATION: Xaa 
KEY: MISC FEATURE 
(2) . . 
INFORMATION: Xaa 
KEY: MISC FEATURE 
(5) . . 
OTHER INFORMATION: Xaa 
Cha (cyclohexylalanine) 
di - chloro-phenylalanine carboxamide 
ORGANISM: Artificial Sequence 
RMATION: Non-natural peptide 
Cha (cyclohexylalanine) 
di - chloro-phenylalanine carboxamide 
ORGANISM: Artificial Sequence 
INFORMATION: Non-natural sequence 
Cha (cyclohexylalanine) 
di - chloro-phenylalanine carboxamide 
US 9,133,240 B2 
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- Continued 
<4 OOs, SEQUENCE: 26 
Glin Xaa Arg Lieu. Xaa 
1. 5 
<210s, SEQ ID NO 27 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural sequence 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (3) ... (3) 
<223> OTHER INFORMATION: Xaa = Cha (cyclohexylalanine) 
<4 OOs, SEQUENCE: 27 
Arg Glin Xaa Lys Lieu. Phe 
1. 5 
<210s, SEQ ID NO 28 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural sequence 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (3) ... (3) 
223 OTHER INFORMATION: Xaa 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (6) . . (6) 
223 OTHER INFORMATION: Xaa 
Cha (cyclohexylalanine) 
beta homophenylalanine 
<4 OOs, SEQUENCE: 28 
Arg Glin Xaa Lys Lieu. Xaa 
1. 5 
<210s, SEQ ID NO 29 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural sequence 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (3) ... (3) 
<223> OTHER INFORMATION: Xaa = Cha (cyclohexylalanine) 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (4) . . (6) 
<223> OTHER INFORMATION: The peptide is cyclized between residues K. 
and F 
<4 OOs, SEQUENCE: 29 
Arg Glin Xaa Lys Lieu. Phe 
1. 5 
<210s, SEQ ID NO 3 O 
60 
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&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural peptide 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (3) ... (3) 
<223> OTHER INFORMATION: Xaa = Cha (cyclohexylalanine) 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (4) . . (6) 
<223> OTHER INFORMATION: The peptide is cyclicized between residues K 
and beta homophenylalanine 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (6) . . (6) 
<223> OTHER INFORMATION: Xaa = beta homophenylalanine 
<4 OOs, SEQUENCE: 30 
Arg Glin Xaa Lys Lieu. Xaa 
1. 5 
<210s, SEQ ID NO 31 
&211s LENGTH: 4 
212. TYPE: PRT 
<213> ORGANISM: Escherichia coli 
<4 OOs, SEQUENCE: 31 
Ala Ser Arg Glin 
1. 
<210s, SEQ ID NO 32 
&211s LENGTH: 7 
212. TYPE: PRT 
<213> ORGANISM: Escherichia coli 
<4 OOs, SEQUENCE: 32 
Arg Glin Lieu Val Lieu. Gly Lieu 
1. 5 
<210s, SEQ ID NO 33 
&211s LENGTH: 5 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural peptide 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (1) . . (1) 
<223 is OTHER INFORMATION: Xaa = Cha 
<4 OOs, SEQUENCE: 33 
Xaa Phe Glin Lieu. Asp 
1. 5 
<210s, SEQ ID NO 34 
&211s LENGTH: 30 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
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<4 OOs, SEQUENCE: 34 
gtaaaacgac ggc.cagtgcc aagct tagt c 3 O 
<210s, SEQ ID NO 35 
&211s LENGTH: 90 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic primer 
<4 OOs, SEQUENCE: 35 
c catgattac gaatticagtic at Caccggcg C cacagacta agcttggcac tdgc.cgt.cgt. 6 O 
tttacaacgt. c9tgactggg aaaac cctgg 9 O 
<210s, SEQ ID NO 36 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural peptide 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
223 OTHER INFORMATION: ACETYLATION 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (3) ... (3) 
<223 is OTHER INFORMATION: Xaa = Cha 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (6) . . (6) 
223s OTHER INFORMATION: Xaa = di CF 
<4 OOs, SEQUENCE: 36 
Arg Glin Xaa Asn Lieu. Xaa 
1. 5 
<210s, SEQ ID NO 37 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural peptide 
22 Os. FEATURE: 
<221s NAME/KEY: MOD RES 
<222s. LOCATION: (1) . . (1) 
<223> OTHER INFORMATION: Addition of a cinnamoyl group 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (3) ... (3) 
<223 is OTHER INFORMATION: Xaa = Cha 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<222s. LOCATION: (6) . . (6) 
223s OTHER INFORMATION: Xaa = di CF 
<4 OO > SEQUENCE: 37 
Arg Glin Xaa Asn Lieu. Xaa 
1. 5 
<210s, SEQ ID NO 38 
&211s LENGTH: 6 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Non-natural peptide 
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FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (3) ... (3) 
OTHER INFORMATION: Xaa = Cha 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (6) . . (6) 
OTHER INFORMATION: Xaa = di CF 
SEQUENCE: 38 
Arg Glin Xaa Arg Lieu. Xaa 
1. 5 
SEO ID NO 39 
LENGTH: 6 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Non-natural peptide 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (3) ... (3) 
OTHER INFORMATION: Xaa = Cha 
SEQUENCE: 39 
Arg Glin Xaa Arg Lieu Phe 
1. 5 
SEQ ID NO 4 O 
LENGTH: 6 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Non-natural peptide 
FEATURE: 
NAME/KEY: MOD RES 
LOCATION: (1) ... (1) 
OTHER INFORMATION: ACETYLATION 
FEATURE: 
NAME/KEY: MISC FEATURE 
LOCATION: (3) ... (3) 
OTHER INFORMATION: Xaa = Cha 
SEQUENCE: 4 O 
Arg Glin Xaa Lys Lieu. Phe 
1. 5 
The invention claimed is: 
1. A compound of formula (I) 
O RI 
R N"-n O1, NH 
O O pi 
66 
- Continued 
-continued 
R2 O R4 
55 Gln NH NH 
1. NNH NH this 
O R3 O R5 
60 (I) 
wherein 
Gln is glutamine; 
R is selected from the group consisting of a C2-alkyl 
65 group optionally substituted by a Co-aryl group, a 
C-2-alkenyl group optionally Substituted by a Co 
aryl group, a C-6-cycloalkyl group, a Co-o-aryl group 
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optionally Substituted by a C-alkyl, and a C-s-alkyl 
(O—CH2—CH) group with theing an integer from 
0 to 20 inclusive; 
R" is the side chain of arginine or lysine; 
R is a -(CH2)—Cle-cycloalkyl group optionally substi 
tuted by a halogen and/or by a group selected from the 
group consisting of NH, -NH CO. R. —COH, 
NHR and NR'R'', wherein RandR are indepen 
dently a C-alkyl group; 
R is selected from the group consisting of a C-s-alkyl 
group, the side chain of arginine or lysine, -(CH2)- 
COR7, -(CH.) CO. NHR'. , -CHOR and 
—(CH2) NHR'. wherein 
q is 1, 2, 3 or 4. 
R" is a hydrogen atom, a C-8-alkyl group, a C4-12 
alkylene group forming together with Ra lactone or 
a polyether ring, or a C2-alkenylene, forming 
together with Ralactone or a polyether ring, 
R’ is a hydrogenatom, a C-s-alkyl group, or -(CH2)g 
—NH with q' being an integer between 2 and 8 
inclusive and forming together with Ralactam, 
R is a hydrogen atom, a C-s-alkyl group, a C4-12 
alkylene group forming together with R a lactone or 
a polyether ring, or a C2-alkenylene, forming 
together with Ralactone or a polyether ring, 
R is a hydrogen atom, or R together with R form a 
lactam, 
R" is a C-s-alkyl group optionally substituted by a C 
cycloalkyl group, or a halogen-Ca-alkyl group: 
R is selected from the group consisting of a -(CH2)— 
C-cycloalkyl group; —(CH-CH)—C-cy 
cloalkyl group; a —(CH2)—Co-aryl group optionally 
Substituted by a halogen, a C- alkyl group and/or a C 
alkoxy group; a —(CH-CH)—Co-aryl group 
optionally substituted by a halogen, a C- alkyl group 
and/or a C- alkoxy group; a —(CH2)—Co-het 
eroaryl group optionally Substituted by a halogen and/or 
a C- alkyl group; and a —(CH2—CH2)—Cs-o-het 
eroaryl group optionally Substituted by a halogen and/or 
a C- alkyl group: 
R is COH, COR', CO. NH CO. NHR'. 
—OR' when ris 1 or 2, -NH CO. NHR' when ris 
1 or 2, or R is CO , —CO-O or —O— and 
forms a lactam, a lactone, or a polyether ring with R', 
R7, R or R; wherein 
R" is a C-s-alkyl group optionally substituted by a 
Co-aryl group; a C-cycloalkyl group; a Co 
aryl group optionally Substituted by a halogen, a C 
alkyl group and/or a C2-alkoxy group; 
m is 0 or 1; 
n is an integer from 0 to 9 inclusive; 
p is an integer from 0 to 10 inclusive; 
r is 0, 1 or 2. 
2. The compound of claim 1, wherein 
R is a Cis-alkyl group optionally Substituted by a Co 
aryl group, a C-s-alkenyl group optionally substituted 
by a Co-aryl group or a C-alkyl-(O—CH2— 
CH), — group with t being an integer from 0 to 10 
inclusive. 
3. The compound of claim 1, wherein 
R is a C-alkyl group optionally substituted by a Co 
aryl group or a C-alkenyl group optionally substituted 
by a Co-o-aryl group. 
4. The compound of claim 1, wherein n is an integer com 
prised between 1 and 5 inclusive. 
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5. The compound of claim 1, wherein n is 0. 
6. The compound of claim 1, wherein 
R is a -(CH2)—C-cycloalkyl group. 
7. The compound of claim 1, wherein 
R" is a C-s-alkyl group or a C2-alkyl group optionally 
Substituted by a C-cycloalkyl group. 
8. The compound of claim 1, wherein 
R is a -(CH2)—Co-aryl group optionally substituted 
by a halogen, a C-2 alkyl group and/or a C-2 alkoxy 
group. 
9. The compound of claim 1, wherein 
R is selected from the group consisting of a C-s-alkyl 
group, the side chain of arginine or lysine, -(CH2) - 
CO.R7, -(CH.), CO. NHR7, -CHOR, and 
—(CH2) NHR'. wherein 
q is 1, 2, 3, 4, 
R" is a hydrogen atom, or a Cis-alkyl group, 
R’ is a hydrogen atom, or a C-s-alkyl group, 
R is a hydrogen atom, a C-s-alkyl group, 
R is a hydrogen atom; 
and 
R° is COH,-COR, CO. NH CO. NHR'. 
—OR' when ris 1 or 2, -NH CO. NHR' when ris 
1 or 2; wherein 
R" is a C-s-alkyl group optionally substituted by a 
Co-o-aryl group; a C-cycloalkyl group; a Co-o- 
aryl group optionally Substituted by a halogen, a C 
alkyl group and/or a C2-alkoxy group. 
10. The compound of claim 1, wherein 
R is selected from the group consisting of the side chain of 
arginine, the side chain of lysine. —(CH) CO.R7 
and -(CH.), CO. NHR', wherein 
q is 1, 2, 3 or 4. 
R" is a hydrogen atom, or a C-s-alkyl group, and 
R’ is a hydrogen atom, or a Cis-alkyl group. 
11. The compound of claim 1, wherein 
Ris-COH or -CO. NH. 
12. The compound of claim 1, wherein 
R is selected from the group consisting of -(CH2) - 
CO.R7, -(CH.), CO. NHR7, -CHOR, and 
—(CH2) NHR'. wherein 
q is 1, 2, 3 or 4. 
R" is a Cas-alkylene group forming together with Ra 
lactone or a polyether ring, or a Cas-alkenylene, 
forming together with Ralactone or apolyether ring, 
R7 is -(CH.) NH- with q' being an integer from 2 
to 8 inclusive and forming together with Ralactam, 
R is a Cas-alkylene group forming together with Ra 
lactone or a polyether ring, or a Cas-alkenylene, 
forming together with Ralactone or a polyether ring, 
R together with R' form a lactam: 
R is —CO , —CO-O or —O—and forms a lactam, 
a lactone, or a polyether ring with R', R', R or R. 
13. The compound of claim 1, which is selected from the 
group consisting of Ac-Gln-Cha-Asp-Leu-Phe (SEQ ID 
NO:7), Ac-Gln-Cha-Asp-Leu-pMePhe (SEQIDNO:11), Ac 
Gln-Cha-Asp-Leu-pClPhe (SEQ ID NO:12), Ac-Gln-Cha 
Asp-Leu-pBrPhe (SEQ ID NO:13). Ac-Gln-Cha-Asp-Leu 
diCIPhe (SEQID NO:14), Ac-Gln-Cha-Asp-hLeu-Phe (SEQ 
ID NO:16), and Ac-Gln-Cha-Asp-Cha-Phe(SEQID NO:17). 
14. The compound of claim 1, wherein the affinity of said 
compound for the interacting pocket of the bacterial Bring is 
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at least twice the affinity of the acetylated peptide of sequence 
AcOLDLF (SEQID NO:6) with said interacting pocket. 
15. A pharmaceutical composition comprising, as an active 
agent, a compound according to claim 1. 
16. A method of treating an infection by E. coli in a subject 5 
in need thereof comprising administering the compound of 
claim 1 to the subject. 
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